US10591489B2 - Method for diagnosing a molecular phenotype of a patient suffering from an illness accompanied by chronic inflammation - Google Patents

Method for diagnosing a molecular phenotype of a patient suffering from an illness accompanied by chronic inflammation Download PDF

Info

Publication number
US10591489B2
US10591489B2 US15/782,595 US201715782595A US10591489B2 US 10591489 B2 US10591489 B2 US 10591489B2 US 201715782595 A US201715782595 A US 201715782595A US 10591489 B2 US10591489 B2 US 10591489B2
Authority
US
United States
Prior art keywords
tbet
gata
patient
gene expression
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US15/782,595
Other versions
US20180031571A1 (en
Inventor
Agnieszka Turowska
Joachim Bille
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sterna Biologicals GmbH
Original Assignee
Sterna Biologicals GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sterna Biologicals GmbH and Co KG filed Critical Sterna Biologicals GmbH and Co KG
Priority to US15/782,595 priority Critical patent/US10591489B2/en
Assigned to STERNA BIOLOGICALS GMBH & CO. KG reassignment STERNA BIOLOGICALS GMBH & CO. KG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BILLE, Joachim, TUROWSKA, Agnieszka
Publication of US20180031571A1 publication Critical patent/US20180031571A1/en
Application granted granted Critical
Publication of US10591489B2 publication Critical patent/US10591489B2/en
Assigned to STERNA BIOLOGICALS GMBH reassignment STERNA BIOLOGICALS GMBH CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: STERNA BIOLOGICALS GMBH & CO. KG
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/127—DNAzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Definitions

  • the invention relates to a method and a kit for diagnosing a molecular phenotype of a patient suffering from an illness accompanied by chronic inflammation as well as a medicament for treating such a patient.
  • Chronic inflammations constitute an increasing medical problem area of high socioeconomic significance. This includes in particular the following groups of illnesses: autoimmune diseases and diseases from the area of rheumatic diseases (manifestations among others on the skin, lungs, kidneys, vascular system, nervous system, connective tissue, locomotor system, endocrine system), immediate-type allergic reactions and asthma, chronic obstructive lung diseases (COPD), arteriosclerosis, psoriasis and contact eczema and chronic rejection reactions after organ and bone marrow transplants. Many of these diseases are showing a rising prevalence in the last decades not only in industrial nations, but sometimes around the world. For example, in Europe, North America, Japan and Australia more than 20% of the population suffers from allergic diseases and asthma.
  • rheumatic diseases manifestations among others on the skin, lungs, kidneys, vascular system, nervous system, connective tissue, locomotor system, endocrine system
  • immediate-type allergic reactions and asthma immediate-type allergic reactions and asthma
  • COPD chronic ob
  • Chronic obstructive lung diseases are currently the fifth most frequent cause of death throughout the world and according to calculations of the WHO they will represent the third most frequent cause of death in the year 2020.
  • Arteriosclerosis with the secondary diseases of cardiac infarction, stroke and peripheral arterial disease leads the world in morbidity and mortality statistics. Together with neurodermatitis, psoriasis and contact eczema are in general the most frequent chronic inflammatory diseases of the skin.
  • A An excessive immune response to what are ordinarily harmless antigens for human beings.
  • antigens can be components of the environment (e.g. allergens such as pollen, animal hairs, food, mites, chemical substances such as preservatives, dyestuffs, detergents).
  • allergens such as pollen, animal hairs, food, mites, chemical substances such as preservatives, dyestuffs, detergents.
  • COPD chronic pulmonary lung diseases
  • the immune system can also react against components of its own organism, recognize them as foreign and initiate an inappropriate inflammatory response. In these cases an autoimmune illness develops.
  • harmless, non-toxic antigens are erroneously as foreign or dangerous and an inappropriate inflammatory response is set in motion.
  • effector mechanisms including, in particular the following functions: antibody production: control of the functionality of effector cells of the immune system (e.g. such as neutrophilic, basophilic, eosinophilic granulocytes), feedback to functions of the innate immune system, influencing of the functionality of non-hematopoietic cells such as e.g. epithelial, endothelial, connective tissue, bones and cartilage and above all neuronal cells.
  • effector cells of the immune system e.g. such as neutrophilic, basophilic, eosinophilic granulocytes
  • non-hematopoietic cells such as e.g. epithelial, endothelial, connective tissue, bones and cartilage and above all neuronal cells.
  • T cells Since the T cells, which have already been mentioned, take over central functions in the course of the disease, an understanding of their specialization is critical.
  • a complex signal transduction cascade is involved in the differentiation of na ⁇ ve CD4 + cells to Th1 or Th2 cells.
  • Th1 cells produce interferon- ⁇ (INF ⁇ ), interleukin 2 (IL-2) and tumor-necrosis-factor- ⁇ , while Th2 cells secrete IL-4, IL-5, IL-9 and IL-13.
  • IFN ⁇ interferon- ⁇
  • IL-2 interleukin 2
  • Th2 cells secrete IL-4, IL-5, IL-9 and IL-13.
  • Bacterial and viral infections induce an immune response which is dominated by Th1 cells.
  • Th2 cells regulate igE production against parasites. In the process there is a balance between Th1 and Th2 cells. The destruction of this balance causes diseases, so an excessive Th1 cell response is associated with autoimmunity diseases, while allergic diseases are at the basis of a reinforced Th2 cell response.
  • Th1 cytokines are involved in the pathogenesis of autoimmune diseases such as e.g. autoimmune uveitis, experimental allergic encephalomyelitis, type 1 diabetes mellitus or Crohn's disease, while Th12 cytokines (IL-4, IL-5, IL-13 or IL-9) are involved in the development of chronic inflammatory respiratory ailments, such as e.g. airway eosinophilia, asthma, mucus hypersecretion and airway hyperresponsiveness. These diseases are brought about by pathophysiological changes during the production of characteristic cytokines by antigen-specific Th cells. Th2 cell sub-populations in the lungs and the airways cause the characteristic symptoms of bronchial asthma in the animal model
  • Th1 cell-specific transcription factor Tbet the Th1 cell-specific transcription factor Tbet and the Th2 cell-specific transcription factor GATA-3.
  • the Th1 cell-specific transcription factor Tbet is primarily responsible for the differentiation of na ⁇ ve CD4 + T cells to Th1 cells. Its expression is controlled via the signal transduction pathways of the T cell receptor (TZR) and via INF ⁇ receptor/STAT1. Tbet transactivates the endogenous INF ⁇ gene and induces INF ⁇ production. The in vivo function of Tbet is confirmed in knock-out mice (Tbet ⁇ / ⁇ ). The quantity of Th2 cytokines is increased in mice that are deficient in Tbet.
  • Tbet in mucosal T cells is known in the development of inflammatory bowel diseases.
  • the transcription factor Tbet specifically induces the development of Th1 cells and controls the INF ⁇ production in these cells. Through the inhibition of Tbet the balance between Th1 and Th2 cells is shifted in favor of the Th2 cells.
  • Th2 cells have an essential function in the development of allergic diseases, in particular various asthma ailments.
  • the differentiation of Th0 cells to Th2 cells necessary for this is dependent on the transcription factor GATA-3.
  • GATA-3 is a member of the GATA family of transcription factors.
  • the Th2 cell-specific transcription factor GATA-3 is primarily responsible for the differentiation of na ⁇ ve CD4 + T cells to Th2 cells.
  • the Th2 cell differentiation is primarily controlled by two signal transmission pathways, the T cell receptor (TZR) and the IL-4 receptor pathway: Signals forwarded from TZR activate the Th2 cell-specific transcription factors cMaf and GATA-3 as well as also the transcription factors NFAT and AP-1.
  • the activation of the IL-4 receptor results in the binding of STAT6 on the cytoplasmic domain of the IL-4 receptor, where it is phosphorylated by Jak1 and Jak3 kinases.
  • GATA-3 is a zinc finger transcription factor which is expressed exclusively in mature Th2 cells, not in Th1 cells.
  • Th2 cells produce cytokines such as for example IL-4, IL-5, IL-6, IL-13 and GM-CSF.
  • the polarization to Th2 inhibits a Th1 differentiation through suppression of Tbet and vice versa.
  • the expression of GATA-3 is not restricted to T cells.
  • An expression of GATA-3 was also able to be confirmed in eosinophilic and basophilic granulocytes, mast cells and epithelial cells.
  • GATA-3 plays a central role in the immunopathogenesis of chronic inflammatory diseases, in particular of allergic asthma.
  • a certain classification of asthma patients is likewise proposed, wherein the gene expression of a plurality of candidate genes, such as for example POSTN, CLCA1 and SERPINB2 is employed. Since it is known that this gene is highly regulated by the Th2 cytokine IL4 or IL-13, the cluster is also referred to as “IL-4/IL-13 signature”.
  • a determination of the values for serum IgE and the number of eosinophilic granulocytes were also described.
  • cytokine IL-5 Another disadvantage of patient stratification on the basis of this gene expression, above all of POSTN, is the fact that along with an “IL-4/IL-13 signature”, the cytokine IL-5 also plays a significant role in the genesis of asthma. In addition, the role of the protein periostin in the immune cascade and thus the pathogenesis is unknown.
  • the patient classified in this manner should be able to be treated with a therapeutic agent that is especially effective specifically for this subgroup.
  • the biomarker should make possible/facilitate an individual prediction about the effectiveness of a therapeutic agent with respect to a patient, in particular an asthma patient.
  • the problem is solved by a method for diagnosing a molecular phenotype of a human patient suffering from an illness accompanied by chronic inflammation, wherein the molecular phenotype is selected from the group consisting of the subgroups “Th2 high”, “Th2 low”, “Th1 high” and “Th1 low” and the gene expression of GATA-3 and/or Tbet is measured in a biological isolate of the patient and used for the assignment to a molecular phenotype of the illness.
  • the more detailed classification of a human patient suffering from an illness accompanied by chronic inflammation occurs in the process by measurement of the gene expression of the transcription factor GATA-3 and/or of the transcription factor Tbet.
  • the Th1 cell-specific transcription factor Tbet and the Th2 cell-specific transcription factor GATA-3 are involved in the development of autoimmune illnesses and chronic inflammation reactions.
  • the polarization to Th2 inhibits a Th1 differentiation through suppression of Tbet and vice versa.
  • an assignment to a molecular phenotype that is, to a subgroup of the illness accompanied by chronic inflammation, can take place.
  • the mentioned molecular phenotyping can be performed without difficulties in a routine clinical setting with a high degree of predictability.
  • the transcription factors GATA-3 and Tbet are the central key molecules in the development of Th1 or Th2 dependent chronic inflammatory diseases. Therefore, the direct measurement of the protein or mRNA expression represents best possible patient stratification approach since no interconnected mechanisms can possible falsify the results.
  • the expression level of GATA-3 and/or Tbet is determined via the protein or mRNA quantity.
  • the protein quantity can be quantitatively determined with the help of an immunoassay.
  • the immunoassay is preferably an enzyme-linked immunosorbent assay (ELISA) test, a radioimmunoassay (RIA), an electrochemiluminescence (ECL) immunoassay, a CLIA (chemoluminescence-linked immunosorbent assay), an FLIA (fluorescence-linked immunosorbent assay) or a multiplex-assay.
  • the mentioned assays offer the advantage of a potential automation and are thus particularly well suited for daily clinical practice.
  • any other suitable test for quantitative determination of the protein quantity of GATA-3 and/or Tbet can be selected within the scope of the present invention.
  • the expression level of GATA-3 and/or Tbet can occur via mass spectrometric methods, chromatographic methods such as gas chromatography, fluid-based methods with solid phase separation, such as HPLC, or microfluidic and nanofluidic methods.
  • the method for determining the expression of GATA-3 or Tbet with the help of an ELISA test can if necessary comprise the following:
  • the second specific antibody can for example be marked with biotin and a separate addition of an enzyme coupled to streptavidin can take place.
  • the second specific antibody can also be directly coupled to an enzyme.
  • a third antibody directed toward the second specific antibody can be used that is coupled to an enzyme.
  • the enzyme is preferably a peroxidase or alkaline phosphatase and is implemented with a suitable substrate that is suitable for colorimetry or chemiluminescence and the like.
  • the mRNA quantity of GATA-3 and/or Tbet can be determined additionally or as an alternative to the mentioned determination of the protein quantity.
  • a PCR particularly preferably a qPCR or a micro-array chip is suitable for this purpose.
  • a person skilled in the art is aware of how to select GATA-3 and Tbet specific probes or primers for the mentioned detection methods.
  • the biological isolate was obtained whole blood, urine, sputum, a bronchial alveolar lavage (BAL), a biopsy, a brush biopsy, liquor, tracheal secretion, seminal fluid, ascitic fluid, saliva, punctate or lymph fluid.
  • BAL bronchial alveolar lavage
  • a person skilled in the art is familiar with the routine methods for obtaining suitable biological isolate.
  • GATA-3 and Tbet are proteins which, as transcription factors, have their effect in the cell core of T helper cells of the subtype Th1 and Tlh2.
  • T helper cells of the subtype Th1 and Tlh2.
  • cells which form GATA-3 and Tbet must first be isolated and subsequently lyzed. A direct confirmation of these proteins from human serum or plasma is hardly possible, since they are not available there in detectable concentration.
  • An analysis of GATA-3 and Tbet therefore takes place if necessary in four stages:
  • the inventive method comprises also one or more of the following steps:
  • steps (i)-(iii) are performed prior to the cell disruption and in each case facilitate an increase in the sensitivity as well as predictability of the diagnostic method, since, in particular in the leukocytes the genes GATA-3 and Tbet are differentially expressed.
  • an assignment of the patient to a molecular phenotype of the subgroup “Th2 high” occurs when at least one of the following conditions is fulfilled:
  • the subgroup “Th2 high” is thus characterized either by a high absolute GATA-3 gene expression in comparison to a defined reference value.
  • a corresponding value of the GATA-3 protein content in the isolate of a healthy person can be used as a reference value.
  • absolute reference values can also be used.
  • absolute reference values such as for example copies/ml can also be used.
  • the inventive method for assigning the patient to the molecular phenotype of the subgroup “Th2 high” comprises the steps:
  • a determination of further parameters for certain placement/classification in the subgroup “Th2 high” can take place.
  • the serum IgE level and the number of eosinophilic granulocytes can be measured.
  • An assignment to the subgroup “Th2 high” takes place additionally whenever the serum IgE level is higher than 100 IU/ml and/or the number of the eosinophilic granulocytes is 0.14 ⁇ 10 9 cells per liter or higher.
  • the concentration in nitric oxide in the exhaled air thus a determination of the FeNO value can be performed.
  • Another advantageous embodiment of the inventive method relates to an assignment of the patient to a molecular phenotype of the subgroup “Th2 low” when at least one of the following conditions is fulfilled:
  • the subgroup “Th2 low” is thus characterized either by a low absolute GATA-3 gene expression in comparison to a defined reference value.
  • a corresponding value of the GATA-3 protein content in the isolate of a healthy person can be used as a reference value.
  • the absolute GATA-3 gene expression will regularly be higher than in an isolate of a healthy patient.
  • the absolute GATA-3 gene expression can also be lower than in the case of a healthy person.
  • the GATA-3 gene expression is also not as high as described for the subgroup “Th2 high”.
  • an assignment of the patient to the subgroup “Th2 low” occurs when said patient's GATA-3 protein content in comparison to an isolate of a healthy person, if at all, is only moderately increased.
  • fixed reference values can also be used.
  • a corresponding value of the GATA-3 mRNA quantity in the isolate of a healthy person can be used as a reference value, wherein an assignment of the patient to the subgroup “Th2 low” takes place when said patient's GATA-3 mRNA quantity is lower than in a corresponding sample of a healthy person or in any event is not significantly increased.
  • fixed reference values can be used.
  • the ratio of GATA-3:Tbet gene expression in the biological isolate is lower than a defined reference value.
  • a corresponding value of the ratio of GATA-3:Tbet gene expression in the isolate of a healthy person can be used as a reference value.
  • the determination of the ratio of GATA-3:Tbet gene expression also increases the certainty of the statement in this case, since in the process along with GATA-3 gene expression as an additional parameter the Tbet gene expression is determined. Since the two transcription factors mutually regulate one another in their expression, as initially described, the inclusion of Tbet constitutes an internal control for the measurement of the GATA-3 gene expression.
  • the inventive method for assigning the patient to the molecular phenotype of the subgroup “Th2 low” comprises the steps:
  • a determination of further parameters for certain placement in the subgroup “Th2 low” can take place.
  • the serum IgE level and the number of eosinophilic granulocytes can be measured.
  • An assignment to the subgroup “Th2 low” takes place additionally whenever the serum IgE level is lower than 100 IU/ml and/or the number of the eosinophilic granulocytes is below 0.14 ⁇ 10 9 cells per liter.
  • the concentration in nitric oxide in the exhaled air thus a determination of the FeNO value can be performed.
  • an assignment of the patient to a molecular phenotype of the subgroup “Th1 high” occurs when at least one of the following conditions is fulfilled:
  • the subgroup “Th1 high” is thus characterized either by a high absolute Tbet gene expression in comparison to a defined reference value.
  • a corresponding value of the Tbet protein content in the isolate of a healthy person can be used as a reference value, wherein an assignment of the patient to the subgroup “Th1 high” takes place when said patient's Tbet protein content is increased.
  • fixed reference values can also be used.
  • a corresponding value of the Tbet mRNA quantity in the isolate of a healthy person can be used as a reference value, wherein an assignment of the patient to the subgroup “Th1 high” takes place when said patient's Tbet mRNA quantity is increased.
  • fixed reference values can also be used.
  • the ratio of Tbet:GATA-3 gene expression in the biological isolate is higher than a defined reference value.
  • a corresponding value of the ratio of Tbet:GATA-3 gene expression in the isolate of a healthy person can be used as a reference value.
  • the determination of the ratio of Tbet:GATA-3 gene expression also increases the certainty of the statement in this case, since in the process along with the Tbet gene expression as an additional parameter the GATA-3 gene expression is determined and the inclusion of GATA-3 constitutes an internal control for the measurement of the Tbet gene expression.
  • the inventive method for assigning the patient to the molecular phenotype of the subgroup “Th1 high” comprises the steps:
  • a further aspect of the present invention relates to a method that facilitates an assignment of the patient to a molecular phenotype of a subgroup “Th1 low” when at least one of the following conditions is fulfilled:
  • the subgroup “Th1 low” is thus characterized either by a low absolute Tbet gene expression in comparison to a defined reference value.
  • a corresponding value of the Tbet protein content in the isolate of a healthy person can be used as a reference value.
  • the absolute Tbet gene expression can however be higher than in an isolate of a healthy person.
  • the absolute Tbet gene expression can also be lower than in the case of a healthy person. In any event, the Tbet gene expression is not as high as described for the subgroup “Th1 high”.
  • an assignment of the patient to the subgroup “Th1 low” takes place when said patient's Tbet protein content in comparison to an isolate of a healthy person, if at all, is increased, however not significantly.
  • fixed reference values can also be used.
  • a corresponding value of the Tbet mRNA quantity in the isolate of a healthy person can be used as a reference value, wherein an assignment of the patient to the subgroup “Th1 low” takes place when said patient's Tbet mRNA quantity is lower than in the corresponding sample of a healthy patient or in any event is not significantly increased.
  • fixed reference values can also be used.
  • the ratio of Tbet:GATA-3 gene expression in the biological isolate is lower than a defined reference value.
  • a corresponding value of the ratio of Tbet:GATA-3 gene expression in the isolate of a healthy person can be used as a reference value.
  • the determination of the ratio of Tbet:GATA-3 gene expression also increases the certainty of the statement in this case, since in the process along with the Tbet gene expression as an additional parameter the GATA-3 gene expression is determined and the inclusion of GATA-3 constitutes in a certain sense an internal control for the measurement of the Tbet gene expression.
  • the inventive method for assigning the patient to the molecular phenotype of the subgroup “Th1 low” comprises the steps:
  • a determination of further parameters for certain placement in the subgroup “Th1 high” and “Th1 low” can take place.
  • the number of eosinophilic granulocytes or the serum IgE level can be measured.
  • An assignment to the subgroup “Th1 high” takes place when the serum IgE level is lower than 100 IU/ml and/or the number of the eosinophilic granulocytes is below 0.14 ⁇ 10 9 cells per liter. Otherwise, an assignment to the subgroup “Th1 low” takes place.
  • the concentration in nitric oxide in the exhaled air thus a determination of the FeNO value can be performed.
  • a standardization of the concentrations of GATA-3 and Tbet can be performed. Differences in the sample preparation can for example come about through differing cell numbers that are lyzed, through differing lysis efficiencies of the individual samples or through differing content in the various cell types within the cell preparations.
  • possibilities for standardization include the following: Standardization to the total protein content of the cell lysate, standardization to the cell number that has been lyzed or standardization to the concentration of specific marker proteins that are specifically found in specified cell types.
  • patients with the diagnosed molecular phenotype of the subgroup “Th2 high” can under circumstances simultaneously be placed in the subgroup “Th1 low”. Also, patients with the diagnosed molecular phenotype of the subgroup “Th1 high” can under circumstances simultaneously be placed in the subgroup “Th2 low”. This is to be attributed to the fact represented above that the polarization to Th2 inhibits a Th1 differentiation through suppression of Tbet and vice versa.
  • illnesses are diagnosed or treated that are accompanied by chronic inflammations, such as autoimmune diseases and diseases from the area of rheumatic diseases (manifestations among others on the skin, lungs, kidneys, vascular system, nervous system, connective tissue, locomotor system, endocrine system), immediate-type allergic reactions and asthma, chronic obstructive lung diseases (COPD), arteriosclerosis, psoriasis and contact eczema as well as chronic rejection reactions after organ and bone marrow transplants.
  • rheumatic diseases manifestations among others on the skin, lungs, kidneys, vascular system, nervous system, connective tissue, locomotor system, endocrine system
  • immediate-type allergic reactions and asthma immediate-type allergic reactions and asthma
  • COPD chronic obstructive lung diseases
  • arteriosclerosis psoriasis and contact eczema
  • chronic rejection reactions after organ and bone marrow transplants.
  • tumor diseases can be diagnosed and treated in accordance with the invention, provided GATA
  • the chronic inflammatory disease is either Th2-induced, such as for example allergic bronchial asthma, rhinoconjunctivitis, allergic sinusitis, atopical dermatitis, food allergies, pemphigus, ulcerative colitis, parasitic illnesses, or Th1-induced, such as for example psoriasis, allergic contact eczema, Crohn's disease, COPD, rheumatoid arthritis, autoimmune diseases, type 1 diabetes mellitus or MS.
  • Th2-induced such as for example allergic bronchial asthma, rhinoconjunctivitis, allergic sinusitis, atopical dermatitis, food allergies, pemphigus, ulcerative colitis, parasitic illnesses
  • Th1-induced such as for example psoriasis, allergic contact eczema, Crohn's disease, COPD, rheumatoid arthritis, autoimmune diseases, type 1 diabetes mellitus or MS.
  • the aforementioned problem is additionally solved in accordance with the invention through a medicament for the treatment of illnesses of a human patient with a molecular phenotype that are accompanied by chronic inflammations, wherein the molecular phenotype has been determined in accordance with one or more embodiments of the mentioned inventive diagnostic method.
  • the identified molecular phenotype comprises in the process in particular the groups “Th1 low, “Th1 high”, “Th2 low” or “Th2 high”.
  • the mentioned medicament contains a specific ribonucleic acid or deoxyribonucleic acid specific for GATA-3 or Tbet, in particular a DNAzyme specific for GATA-3 or Tbet.
  • the “10-23” model represents a general DNAzyme model (Sontoro et al., 1997).
  • DNAzymes of the 10-23 model—also referred to as “10-23 DNAzymes” have a catalytic domain of 15 nucleotides, which are flanked by two substrate binding domains.
  • the catalytic domain in the process preferably has the sequence ggctagctacaacga (SEQ ID No. 154).
  • the length of the substrate binding domains is variable: they are either of equal length or variable in length. In one preferred design, the length of the substrate binding domains ranges between 6 and 14 nucleotides, very especially preferably in each case at least nine nucleotides.
  • Such DNAzymes comprise the general sequence nnnnnnnnnggctagctacaacgannnnnnnnnn (SEQ ID NO 155). Especially preferable in the process are substrate binding domains that bind the mRNA, coding for the proteins GATA-3 and Tbet.
  • the specified catalytic central domain ggctagctacaacga is only one preferred embodiment. A person skilled in the art is aware of the fact that “10-23 DNAzymes” can be obtained with comparable biological activity with a modified catalytic domain.
  • the substrate binding domains are completely complementary to the region that flanks the cleaving site.
  • the DNAzyme does not necessarily have to be completely complementary.
  • DNAzymes of the 10-23 type cleave the target mRNA on purine-pyrimidine sequences.
  • the DNAzymes preferably comprise the in vivo active DNAzymes against GATA-3 and Tbet in accordance with WO 2005/033314 A2, whose content is incorporated as disclosure content of the present invention.
  • a medicament for specific inhibition of the GATA-3 expression in vivo contains in particular at least one DNAzyme selected from the group consisting of DNAzymes with a sequence in accordance with one of the sequences SEQ ID NO 1 through SEQ ID NO 70.
  • a DNAzyme binds preferably on an mRNA which codes for a human GATA-3 gene with a gene sequence selected from the sequences SEQ ID NO 151 (human GATA-3 from database no.: XM_043124), SEQ ID NO 152 (human GATA-3 from Database No.: X58072) and SEQ ID NO 153 (human GATA-3, sequenced from plasmid pCR2.1).
  • a medicament for specific inhibition of the GATA-3 expression in vivo preferably contains the DNAzyme hgd40 with the sequence 5′-GTGGATGGAggctagctacaacgaGTCTTGGAG (SEQ ID NO 40).
  • a medicament for specific inhibition of the Tbet expression in vivo contains in particular at least one DNAzyme selected from the group consisting of DNAzymes with a sequence according to one of the sequences SEQ ID NO 71 through SEQ ID NO 148.
  • a DNAzyme preferably binds on an mRNA which codes for a human Tbet gene with a gene sequence selected from the sequences SEQ ID NO 149 (human Tbet from the Database No.: NM_013351) and SEQ ID NO 150 (human Tbet sequenced from pBluescript-SK).
  • a medicament for specific inhibition of the Tbet expression in vivo contains preferably the DNAzyme td69 with the sequence 5′-GGCAATGAAggctagctaccaacgaTGGGTTTCT (SEQ ID NO 139) or td70 with the sequence 5′-TCACGGCAAggctagctacaacgaGAACTGGGT (SEQ ID No 140).
  • the medicament for specific inhibition of the GATA-3 or Tbet expression can contain a suitable siRNA.
  • the medicament preferably has a formulation with which the mentioned specific ribonucleic acid or deoxyribonucleic acid molecules can be administered to the patient in the form of a pharmaceutically acceptable composition either orally, rectally, parenterally, intravenously, intramuscularly or subcutaneously, intracisternally, intravaginally, intraperitoneally, intrathecally, intravascularly, locally (powder, ointment or drops) or in the form of a spray.
  • a pharmaceutically acceptable composition either orally, rectally, parenterally, intravenously, intramuscularly or subcutaneously, intracisternally, intravaginally, intraperitoneally, intrathecally, intravascularly, locally (powder, ointment or drops) or in the form of a spray.
  • a pharmaceutically acceptable composition either orally, rectally, parenterally, intravenously, intramuscularly or subcutaneously, intracisternally, intravaginally, intraperitoneally, intrathecally,
  • the medicament can be used for therapy for all diseases that are accompanied by chronic inflammations.
  • the treatment of the patients takes place with a molecular phenotype of the subgroup “Th2 high” with a GATA-3 specific DNAzyme.
  • the therapy of a patient with a molecular phenotype of the subgroup “Th1 high” takes place with a Tbet specific DNAzyme.
  • the treatment of a patient with the molecular phenotype of the subgroup “Th2 low” can take place with a Tbet specific DNAzyme and the treatment of a patient with the molecular phenotype of the subgroup “Th1 low” can occur with a GATA-3 DNAzyme.
  • An inventive medicament with a GATA-3 specific DNAzyme is thus provided preferably for the treatment of a patient with the molecular phenotype of the subgroup “Th2 high” and a medicament with a Tbet specific DNAzyme is preferably provided for the treatment of a patient with the molecular phenotype of the subgroup “Th1 high”.
  • one special advantage of the medicament according to an embodiment mentioned above for the specific therapy of an inventively diagnosed subgroup of patients—namely “Th2 high”, “Th2 low”, “Th1 high” or “Th1 low” lies in the fact that with the help of the specific medicament, in particular of a DNAzyme and/or an siRNA, a functional inactivation of the coding ribonucleic acid molecules of transcription factors takes place, whose differential expression was determined beforehand and which is involved in the development of the chronic inflammatory reactions and autoimmune diseases.
  • Dosage forms of the inventive medicament comprise pharmaceutically acceptable compositions which contain modifications and “prodrugs”, provided they do not trigger excessive toxicity, irritations or allergic reactions in patients according to reliable medical assessment.
  • the term “prodrug” relates to compounds that are transformed for improvement of the absorption, such as for example through hydrolysis in the blood.
  • the inventive medicament can also be used in the form of a multiple emulsion for application of the mentioned specific nucleic acid molecules.
  • a suitable multiple emulsion to this end comprises an exterior water phase W1, an oil phase O dispersed in the exterior water phase W1 and an interior water phase W2 dispersed in the oil phase O, wherein in the interior water phase W2 at least one electrolyte selected from the group of alkali metal halides and earth alkali metal halides and sulfates and at least one specific ribonucleic acid or deoxyribonucleic acid molecule, preferably a DNAzyme specific for GATA-3 or Tbet is provided, wherein the exterior water phase W1 contains a hydrophilic emulsifier which is a polymer of ethylene oxide and propylene oxide, and the oil phase O is formed by triacylglycerides and has a lipophilic emulsifier from the group of dimethicones.
  • the type of dosage will be determined by the attending physician in accordance with the clinical factors.
  • a person skilled in the art is aware of the fact that the type of dosage is dependent on different factors such as e.g. body size, weight, body surface, age, sex or the general health of the patient, but also depends on the agent to be administered, the duration and type of administration and on other medicaments that may be administered in parallel.
  • the quantity of the active ingredient of the medicament can be adapted to the measured expression level.
  • the subgroup “Th2 high” and an established very high GATA-3 gene expression an increase dose of the active ingredient, in particular a DNAzyme specific for GATA-3 specific can be administered.
  • an increased dose of the active ingredient, in particular of a DNAzyme specific for Tbet can be administered.
  • a further aspect of the present invention relates to a kit for diagnosing a molecular phenotype of a human patient suffering from an illness accompanied by chronic inflammation, wherein the kit contains at least one specific component for quantitative determination of the protein or mRNA quantity of GATA-3 and/or Tbet in a biological isolate of the patient.
  • the inventive kit for diagnosis can be easily offered in the form of a ready to use “kit” which comprises antibodies or antigens that are adsorbed on a surface of a carrier and a preparation of human IgG antibodies which e.g. in the case of a human, a preparation of anti-human IgG antibodies that are marked such that they are proved by a cascade of reactions of the type biotin-streptavidin peroxidase or alkaline phosphatase.
  • the kit for diagnosis also comprises, in addition to a carrier, buffers and reagents, e.g. reagents which are necessary for proof of the reaction such as e.g. streptavidin that is coupled to a marker that gives a color reaction.
  • reagents e.g. reagents which are necessary for proof of the reaction such as e.g. streptavidin that is coupled to a marker that gives a color reaction.
  • the kit additionally comprises a standard sample of GATA-3 and/or Tbet for calibration of the kit, wherein for proof of the protein or mRNA of GATA-3 and/or Tbet, a standard sample is used.
  • a specific antibody against GATA-3 and/or Tbet is included for the quantitative determination of the protein quantity. If necessary, in accordance with a modification, further components for execution of an immunoassay, in particular an ELISA, can be included.
  • the further component for carrying out the ELISA is selected from the group consisting of lysis buffers for cell disruption, a microwell plate, protein quantity standards for GATA-3 and/or Tbet, secondary antibodies and a coupled enzyme for implementation of a substrate for detection.
  • the kit comprises a further specific antibody against GATA-3 or Tbet.
  • the kit can contain a sequence specific probe and/or primer for the GATA-3 and/or Tbet genes for quantitative determination of the mRNA quantity.
  • FIG. 1 shows the influence of various detergents on the release of GATA-3 from stimulated Jurkat cells
  • FIGS. 2 a,b show results of a quantification of Tbet and GATA-3 by means of chromogenic sandwich ELISA
  • FIG. 3 shows a standard curve of a GATA-3 ELISA for quantification of samples
  • FIG. 4 shows a standard curve of a Tbet ELISA for quantification of samples
  • FIG. 5 shows a standardized determination of Tbet in lysates of human peripheral mononuclear cells (PBMC)
  • FIG. 6 shows a significant improvement of allergic airway inflammation after four-day treatment with the GATA-3 specific DNAzyme hgd40 (SEQ ID NO 40) compared to untreated mice
  • FIG. 7 shows the influence of the GATA-3 specific DNAzyme hgd40 (SEQ ID NO 40) on the number of neutrophils occurring in the chronic inflammation, the number of eosinophils in the BAL and the release of IL-5 after an eight-week treatment and
  • FIG. 8 shows the influence of the GATA-3 specific DNAzyme hgd40 (SEQ ID NO 40) on the peribronchial/perivascular inflammation and goblet cell hyperplasia in the lung tissue.
  • Cells can be isolated, for example, by means of technologies based on the binding of specific antibodies. Magnetic beads, which can be obtained from the firms Miltenyi (Macs-System), Dynal (DynaBeads) or BD-Bioscience (iMAG), are used. As an alternative this happens via a cell purification by means of fluorescent marked antibodies on cell sorters for example from the firm Cytomation (MOFLO) or BD-Bioscience (FACS-Vantage). The purity of the target cells is preferably at least 80%, more strongly preferred at least 95% and most preferred at least 99%.
  • RNA isolation Methods for the isolation of RNA are e.g. described in Sambrook and Russell, Molecular Cloning, A Laboratory Manual, 3 rd Edition, Cold Spring Harbor Laboratory (2001), New York and Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons (1998), New York.
  • kits Silika-Technologie
  • RNeasy Kit from the firm Qiagen
  • mRNA directly from the target cells by using commercial kits for example from the firm Qiagen (Oligotex mRNA Kit), Promega (PolyATract mRNA Isolation System) or Miltenyi (mRNAdirect).
  • GATA-3 and Tbet are proteins that, as transcription factors, have their effect in the cell core of T helper cells of the subtype Th1 and Th2.
  • T helper cells of the subtype Th1 and Th2.
  • cells which form GATA-3 and Tbet must first be isolated and subsequently lyzed. A direct proof of these proteins from human serum or plasma is not possible, since they are not present there in detectable concentration.
  • An analysis of GATA-3 and Tbet therefore takes place in 4 stages:
  • buffers containing detergents could be:
  • the concentration of the two transcription factors GATA-3 and Tbet can be determined with different methods.
  • the concentration of the two transcription factors GATA-3 and Tbet can be determined with different methods.
  • FIG. 2 a and FIG. 2 b show the results of a quantification of Tbet and GATA-3 by means of chromogenic sandwich ELISA.
  • the cells were obtained from whole blood through Ficoll density gradient centrifugation.
  • the cells (stimulated human mononuclear cells) were lyzed with a Ripa buffer.
  • the lysate was examined with two ELISA prototype methods with respect to the concentration of GATA-3 and Tbet. The concentration of the two proteins was depicted with respect to the total protein concentration of the cell lysates (standardization to protein content).
  • Th1 cells have a higher content of Tbet (circa 160 ng/ml analyte/mg protein) than Th2 cells (circa 56 ng/ml analyte/mg protein) and this fact can be clearly confirmed from the results of the ELISA test:
  • the Tbet content in the Th1 cells is thus more than two times greater, namely by a factor of about three, than in the Th2 cells.
  • the content in GATA-3 in the Th2 cells (circa 10 ng/ml analyte/mg protein) is higher than in Th1 cells (circa 6 ng/ml analyte/mg protein)
  • the GATA-3 content is more than 1.5 times higher in the Th2 cells here—namely by a factor of about 1.7—than in Th1 cells.
  • the quantity ratio of Tbet:GATA-3 in Th1 cells differs significantly form the corresponding ratio in Th2 cells.
  • the quantity ratio of Tbet:GATA-3 here in Th1 cells is about 27, thus more than 20, while the corresponding quantity ratio in Th2 cells is circa 6, thus less than 10.
  • GATA-3 and Tbet occurs in each case by means of a sandwich ELISA (Enzyme linked immune sorbent assay).
  • the wells of a 96 well microwell plate are coated with specific antibodies against GATA-3.
  • GATA-3 binds on the antibodies on the 96 well plate.
  • a wash step to remove the non-bound substances a second, specific biotinylated antibody against GATA-3 is added.
  • peroxidase marked streptavidin is added.
  • a last wash step to remove the non-bound substances substrate is added.
  • the color development is terminated after a defined time by adding a stop solution. The intensity of the color development is quantified by a microwell plate reader. The quantification of the samples occurs by a comparison to the included standards of known protein concentration.
  • FIG. 3 shows a corresponding standard curve of a GATA-3 ELISA.
  • the steps relate to the following in detail:
  • the verification of the Tbet protein is executed in accordance with the following test principle:
  • the quantitative determination of Tbet occurs by means of a sandwich ELISA (Enzyme linked immuno sorbent assay). To this end the wells of a 96 well microwell plate are coated with specific antibodies against Tbet. After addition of the sample or of a standard, Tbet binds on the antibodies on the 96 well plate. After a wash step to remove the non-bound substances a second, specific antibody against Tbet is added. After an additional wash step to remove the non-bound substances a peroxidase marked antibody against the Tbet specific antibody is added. After a last wash step to remove the non-bound substances substrate is added.
  • the color development is terminated after a defined time by adding a stop solution. The intensity of the color development is quantified by a microwell plate reader. The quantification of the samples occurs by a comparison to the included standards of known protein concentration.
  • FIG. 4 shows a corresponding standard curve of a Tbet ELISA.
  • Possibilities for standardization include the following:
  • FIG. 5 shows a standardized determination of Tbet in lysates of human peripheral mononuclear cells (PBMC).
  • PBMC peripheral mononuclear cells
  • the Tbet concentration was thus reduced in the case of allergy sufferers by more than a factor of 2 compared to healthy subjects. Consequently, an assignment of the patients to the molecular phenotype “Th1 low” is easily possible here, since the Tbet gene expression in the biological isolate is lower than a defined reference value, here the Tbet gene expression of healthy subjects.
  • Th1/Th2 cells are enriched by means of magnetic beads coated with cell specific antibodies for the sample preparation. Subsequently the verification of GATA-3 occurred in accordance with the provision according to Example 2.
  • Example 4 leukocytes are enriched by means of size exclusion filtration for the sample preparation. Subsequently the verification of GATA-3 occurred in accordance with the provision according to Example 2.
  • a GATA-3 specific DNAzyme shows therapeutic effects in the mouse model of the OVA induced allergic airway inflammation of the “Th2 high” phenotype.
  • mice were sensitized with the model allergen ovalbumin (OVA) in the presence of the adjuvant AI(OH) 3 on days 0, 14 and 21 through intraperitoneal injection.
  • OVA ovalbumin
  • the mice On days 24-26 the mice inhaled a 1% OVA aerosol in order to cause a Th2 dominated allergic inflammatory reaction in the lungs.
  • the GATA-3 specific DNAzyme hgd40 SEQ ID NO 40
  • PBS PBS
  • the described mouse model is correspondingly characterized by a massive infiltration of eosinophils an Th2 cells in the airways accompanied by a hyperplasia of the mucus forming goblet cells with increased mucus production as well as the formation of an airway hyperresponsiveness.
  • a GATA-3 specific DNAzyme shows significant therapeutic effects in the chronic mouse model of a Th2 dominated allergic airway inflammation.
  • mice were sensitized with the model allergen ovalbumin (OVA) in the presence of the adjuvant AI(OH) 3 on days 0, 14 and 21 through intraperitoneal injection.
  • OVA ovalbumin
  • a chronic inflammation of the airways was caused in the mice.
  • therapy was provided three times a week (until day 121) either with budesonide or the GATA-3 specific DNAzyme hdg40 through intranasal application.
  • FIGS. 7 and 8 after eight weeks of treatment with GATA-3 specific DNAzyme hdg40 (SEQ ID NO 40) the number of eosinophils in the BAL was able to be significantly reduced and in addition a reduction of the number of neutrophils occurring in the chronic inflammation was also observed. This was accompanied by a lowered peribronchial/perivascular inflammation and reduced goblet cell hyperplasia. Simultaneously, in re-stimulated lymphocytes of those treated with hgd40 a reduced release of IL-5 was observed. In the budesonide group, on the other hand no significant improvement of the parameters cold be observed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)

Abstract

Chronic inflammation is an increasing medical problem area of high socioeconomic significance. The invention relates to a method and a kit for diagnosing a molecular phenotype of a patient suffering from an illness accompanied by chronic inflammation, and to a medicament for treating such a patient. To that end, the gene expression of GATA-3 and/or Tbet in a biological isolate of the patient is measured and used for association with a molecular phenotype of the illness.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation of U.S. patent application Ser. No. 14/428,043 filed Mar. 13, 2015, which is a National Phase of PCT/EP2013/068317 filed Sep. 4, 2013 which claims priority to EP 12184500.2 filed Sep. 14, 2012, the disclosures of which are hereby incorporated by reference in their entirety.
INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ON A COMPACT DISC OR AS A TEXT FILE VIA THE OFFICE ELECTRONIC FILING SYSTEM (EFS-WEB)
Incorporated by reference in its entirety is a sequence listing in computer-readable form submitted concurrently herewith and identified as follows: ASCII (text) file named “49433A_SeqListing.txt,” 59,514 bytes, created on Oct. 9, 2017.
BACKGROUND OF THE INVENTION
The invention relates to a method and a kit for diagnosing a molecular phenotype of a patient suffering from an illness accompanied by chronic inflammation as well as a medicament for treating such a patient.
Chronic inflammations constitute an increasing medical problem area of high socioeconomic significance. This includes in particular the following groups of illnesses: autoimmune diseases and diseases from the area of rheumatic diseases (manifestations among others on the skin, lungs, kidneys, vascular system, nervous system, connective tissue, locomotor system, endocrine system), immediate-type allergic reactions and asthma, chronic obstructive lung diseases (COPD), arteriosclerosis, psoriasis and contact eczema and chronic rejection reactions after organ and bone marrow transplants. Many of these diseases are showing a rising prevalence in the last decades not only in industrial nations, but sometimes around the world. For example, in Europe, North America, Japan and Australia more than 20% of the population suffers from allergic diseases and asthma. Chronic obstructive lung diseases are currently the fifth most frequent cause of death throughout the world and according to calculations of the WHO they will represent the third most frequent cause of death in the year 2020. Arteriosclerosis with the secondary diseases of cardiac infarction, stroke and peripheral arterial disease leads the world in morbidity and mortality statistics. Together with neurodermatitis, psoriasis and contact eczema are in general the most frequent chronic inflammatory diseases of the skin.
Due to the interactions between environmental factors and a genetic disposition, which are to date only poorly understood, there are sustained dysregulations of the immune system. In this connection the following common principles can be established for these different diseases:
(A) An excessive immune response to what are ordinarily harmless antigens for human beings. These antigens can be components of the environment (e.g. allergens such as pollen, animal hairs, food, mites, chemical substances such as preservatives, dyestuffs, detergents). In these cases patients develop an allergic reaction. In the case of e.g. active and passive smokers, chronic pulmonary lung diseases (COPD) develop. On the other hand, the immune system can also react against components of its own organism, recognize them as foreign and initiate an inappropriate inflammatory response. In these cases an autoimmune illness develops. In any case, harmless, non-toxic antigens are erroneously as foreign or dangerous and an inappropriate inflammatory response is set in motion.
(B) The diseases run in phases, including initiation, progression of the inflammatory response and the associated destruction and reconstruction with loss of organ functionality (so-called remodeling).
(C) The diseases show patient-specific sub-phenotypic manifestations.
(D) Components of the innate and acquired immunity have a sustained involvement in the initiation, maintenance and destructive and remodeling processes. Under the influence of the innate immunity (important components: antigen-presenting cells with their diverse populations and the complement system) there is an activation and differentiation of the cells of the adaptive immune system (important components: T and B lymphocytes)> The T cells take over central functions in the further course by differentiating in highly specialized effectors.
In this connection they activate and acquire certain effector mechanisms, including, in particular the following functions: antibody production: control of the functionality of effector cells of the immune system (e.g. such as neutrophilic, basophilic, eosinophilic granulocytes), feedback to functions of the innate immune system, influencing of the functionality of non-hematopoietic cells such as e.g. epithelial, endothelial, connective tissue, bones and cartilage and above all neuronal cells. Here there is a special interaction between immune and nervous systems, from which the concept of neuro-immunological interaction in the case of chronic inflammations developed.
Since the T cells, which have already been mentioned, take over central functions in the course of the disease, an understanding of their specialization is critical. A complex signal transduction cascade is involved in the differentiation of naïve CD4+ cells to Th1 or Th2 cells.
The stimulation via the T cell receptor through the corresponding peptide MHC complex induces clonal expansion and programmed differentiation of CD4+ T lymphocytes to T helpers (Th) 1 or Th2 cells. The differentiation of these two sub-types occurs on the basis of their cytokine profiles. Th1 cells produce interferon-γ (INFγ), interleukin 2 (IL-2) and tumor-necrosis-factor-α, while Th2 cells secrete IL-4, IL-5, IL-9 and IL-13. Bacterial and viral infections induce an immune response which is dominated by Th1 cells. On the other hand Th2 cells regulate igE production against parasites. In the process there is a balance between Th1 and Th2 cells. The destruction of this balance causes diseases, so an excessive Th1 cell response is associated with autoimmunity diseases, while allergic diseases are at the basis of a reinforced Th2 cell response.
It is known that Th1 cytokines are involved in the pathogenesis of autoimmune diseases such as e.g. autoimmune uveitis, experimental allergic encephalomyelitis, type 1 diabetes mellitus or Crohn's disease, while Th12 cytokines (IL-4, IL-5, IL-13 or IL-9) are involved in the development of chronic inflammatory respiratory ailments, such as e.g. airway eosinophilia, asthma, mucus hypersecretion and airway hyperresponsiveness. These diseases are brought about by pathophysiological changes during the production of characteristic cytokines by antigen-specific Th cells. Th2 cell sub-populations in the lungs and the airways cause the characteristic symptoms of bronchial asthma in the animal model
Among other things, two transcription factors are involved in the development of autoimmune diseases and chronic inflammatory reactions: the Th1 cell-specific transcription factor Tbet and the Th2 cell-specific transcription factor GATA-3.
The Th1 cell-specific transcription factor Tbet is primarily responsible for the differentiation of naïve CD4+ T cells to Th1 cells. Its expression is controlled via the signal transduction pathways of the T cell receptor (TZR) and via INFγ receptor/STAT1. Tbet transactivates the endogenous INFγ gene and induces INFγ production. The in vivo function of Tbet is confirmed in knock-out mice (Tbet−/−). The quantity of Th2 cytokines is increased in mice that are deficient in Tbet.
The function of Tbet in mucosal T cells is known in the development of inflammatory bowel diseases. The transcription factor Tbet specifically induces the development of Th1 cells and controls the INFγ production in these cells. Through the inhibition of Tbet the balance between Th1 and Th2 cells is shifted in favor of the Th2 cells.
Many inflammatory diseases on the other hand, such as allergic asthma for example, are associated with an activation of Th2 cells. Th2 cells have an essential function in the development of allergic diseases, in particular various asthma ailments. The differentiation of Th0 cells to Th2 cells necessary for this is dependent on the transcription factor GATA-3. GATA-3 is a member of the GATA family of transcription factors.
The Th2 cell-specific transcription factor GATA-3 is primarily responsible for the differentiation of naïve CD4+ T cells to Th2 cells. In the process, the Th2 cell differentiation is primarily controlled by two signal transmission pathways, the T cell receptor (TZR) and the IL-4 receptor pathway: Signals forwarded from TZR activate the Th2 cell-specific transcription factors cMaf and GATA-3 as well as also the transcription factors NFAT and AP-1. The activation of the IL-4 receptor results in the binding of STAT6 on the cytoplasmic domain of the IL-4 receptor, where it is phosphorylated by Jak1 and Jak3 kinases. The phosphorylation for its part results in the dimerization and translocation of STAT6 to the nucleus, where STAT6 activates the transcription of GATA-3 and other genes. GATA-3 is a zinc finger transcription factor which is expressed exclusively in mature Th2 cells, not in Th1 cells.
Th2 cells produce cytokines such as for example IL-4, IL-5, IL-6, IL-13 and GM-CSF. The polarization to Th2 inhibits a Th1 differentiation through suppression of Tbet and vice versa. However, the expression of GATA-3 is not restricted to T cells. An expression of GATA-3 was also able to be confirmed in eosinophilic and basophilic granulocytes, mast cells and epithelial cells. GATA-3 plays a central role in the immunopathogenesis of chronic inflammatory diseases, in particular of allergic asthma.
Established preparations for the treatment of chronic inflammatory diseases are among others Corticosteroids, anti-leukotrienes, immunosuppressives and Anti-IgE monoclonal antibodies. Asthma patients however respond with varying degrees of success to these therapeutic agents. For a long time the question of what these differences in effectiveness were to be attributed to has remained unresolved. As a consequence, the appropriate therapy had to be fine-tuned on the patient more or less in accordance with the principle of “trial and error”.
However, only recently was it determined that patients suffering from asthma, for example, could be further divided into subgroups (Woodruff et al., 2009, T-helper Type 2-driven inflammation Defines Major Subphenotypes of Asthma, Am J RespiCrit Care Med, Vol 180, 388-395). Thus, it was shown that there are at least two sub-groups of asthma patients, which were designated as “Th2 high” and “Th2 low”. The subgroup “Th2 high” in the process has an increased expression of the POSTN gene, which codes for the protein periostin, as well as the genes for IL-3 and IL-5. The group “Th2 low” of tested asthma patients shows a low POSTN gene expression, comparable to a control group of healthy persons. These differing molecular phenotypes could be one cause for the different effectiveness of common therapeutic agents. Thus for the subgroup “Th2 high” an improved treatment response to treatment with corticosteroids was determined.
It was also found that two groups of asthma patients, namely “Th2 high” and “Th2 low”, respond with varying degrees of success differently to a therapy with a humanized monoclonal antibody to IL-13 (Corren et al., 2011, Lebrikizumab Treatment in Adults with Asthma, The New England Journal of Medicine, 10.1056/NEJMoa 1106469). In the process, an empirical classification of asthma patients in the group “Th2 high” occurred first, when the values for serum-IgE were higher than 100 IU/ml and the number of eosinophilic granulocytes was at 0.14×109 cells per liter or greater. With corresponding values below these patients were placed in the group “Th2 low”. Alternatively, there was a classification by the serum periostin level, which serves as a surrogate marker for Th2 cytokine IL-13, which is difficult to establish in blood or airway samples. In the process, the fact that IL-13 among others induces in vitro the expression of the periostin coding gene POSTN in epithelial cells (Woodruff et al., 2007, Proc Natl Acad Sci USA, 104(40):15858-63. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids). In accordance with Corren et al., 2011, patients with a serum periostin level above the average were placed in a “periostin high” group. For the mentioned sub-groups “Th2 high” and “Periostin high” a better treatment response to treatment with Anti-IL-13 antibodies by tendency was described.
According to WO 2009/124090 A1, a certain classification of asthma patients is likewise proposed, wherein the gene expression of a plurality of candidate genes, such as for example POSTN, CLCA1 and SERPINB2 is employed. Since it is known that this gene is highly regulated by the Th2 cytokine IL4 or IL-13, the cluster is also referred to as “IL-4/IL-13 signature”. Along with the measurement of the serum periostin level as well as the corresponding mRNA quantity, in the process a determination of the values for serum IgE and the number of eosinophilic granulocytes were also described.
One disadvantage of patient stratification on the basis of this gene expression, above all of POSTN, is the fact that along with an “IL-4/IL-13 signature”, the cytokine IL-5 also plays a significant role in the genesis of asthma. In addition, the role of the protein periostin in the immune cascade and thus the pathogenesis is unknown.
Thus the problem arises of finding a biomarker that is suitable for reliable and simultaneously clinically practicable molecular phenotyping of a human patient who is suffering from a disease that is accompanied by chronic inflammations in the groups “Th2 high” or “Th2 low” or “Th1 high” or “Th1 low”. In addition, the patient classified in this manner should be able to be treated with a therapeutic agent that is especially effective specifically for this subgroup. The biomarker should make possible/facilitate an individual prediction about the effectiveness of a therapeutic agent with respect to a patient, in particular an asthma patient.
BRIEF SUMMARY OF THE INVENTION
In accordance with the invention, the problem is solved by a method for diagnosing a molecular phenotype of a human patient suffering from an illness accompanied by chronic inflammation, wherein the molecular phenotype is selected from the group consisting of the subgroups “Th2 high”, “Th2 low”, “Th1 high” and “Th1 low” and the gene expression of GATA-3 and/or Tbet is measured in a biological isolate of the patient and used for the assignment to a molecular phenotype of the illness. The more detailed classification of a human patient suffering from an illness accompanied by chronic inflammation occurs in the process by measurement of the gene expression of the transcription factor GATA-3 and/or of the transcription factor Tbet. As explained initially, the Th1 cell-specific transcription factor Tbet and the Th2 cell-specific transcription factor GATA-3 are involved in the development of autoimmune illnesses and chronic inflammation reactions. The polarization to Th2 inhibits a Th1 differentiation through suppression of Tbet and vice versa. Depending on the expression level of GATA-3 and/or Tbet an assignment to a molecular phenotype, that is, to a subgroup of the illness accompanied by chronic inflammation, can take place. With the inventive diagnostic method the mentioned molecular phenotyping can be performed without difficulties in a routine clinical setting with a high degree of predictability.
The transcription factors GATA-3 and Tbet are the central key molecules in the development of Th1 or Th2 dependent chronic inflammatory diseases. Therefore, the direct measurement of the protein or mRNA expression represents best possible patient stratification approach since no interconnected mechanisms can possible falsify the results.
In accordance with one preferred embodiment of the method, the expression level of GATA-3 and/or Tbet is determined via the protein or mRNA quantity. In the process, the protein quantity can be quantitatively determined with the help of an immunoassay. The immunoassay is preferably an enzyme-linked immunosorbent assay (ELISA) test, a radioimmunoassay (RIA), an electrochemiluminescence (ECL) immunoassay, a CLIA (chemoluminescence-linked immunosorbent assay), an FLIA (fluorescence-linked immunosorbent assay) or a multiplex-assay.
Along with high sensitivity and specificity, the mentioned assays offer the advantage of a potential automation and are thus particularly well suited for daily clinical practice. Of course, if necessary any other suitable test for quantitative determination of the protein quantity of GATA-3 and/or Tbet can be selected within the scope of the present invention. Furthermore, the expression level of GATA-3 and/or Tbet can occur via mass spectrometric methods, chromatographic methods such as gas chromatography, fluid-based methods with solid phase separation, such as HPLC, or microfluidic and nanofluidic methods.
The method for determining the expression of GATA-3 or Tbet with the help of an ELISA test can if necessary comprise the following:
    • Production of a lysate through cell disruption;
    • Addition of the lysate to a recess of a microwell plate which is coated with a first GATA-3 or Tbet specific antibody
    • Washing the microwell plate;
    • Addition of a second GATA-3 or Tbet specific antibody to the recess of the microwell
    • Washing the microwell plate
    • Detection and quantification of the GATA-3 or Tbet protein.
For the purpose of detection, the second specific antibody can for example be marked with biotin and a separate addition of an enzyme coupled to streptavidin can take place. However, the second specific antibody can also be directly coupled to an enzyme. If appropriate, a third antibody directed toward the second specific antibody can be used that is coupled to an enzyme.
The enzyme is preferably a peroxidase or alkaline phosphatase and is implemented with a suitable substrate that is suitable for colorimetry or chemiluminescence and the like.
In accordance with a further aspect of the present invention, the mRNA quantity of GATA-3 and/or Tbet can be determined additionally or as an alternative to the mentioned determination of the protein quantity. Preferably a PCR, particularly preferably a qPCR or a micro-array chip is suitable for this purpose. A person skilled in the art is aware of how to select GATA-3 and Tbet specific probes or primers for the mentioned detection methods.
In accordance with a preferred design of the method, the biological isolate was obtained whole blood, urine, sputum, a bronchial alveolar lavage (BAL), a biopsy, a brush biopsy, liquor, tracheal secretion, seminal fluid, ascitic fluid, saliva, punctate or lymph fluid. A person skilled in the art is familiar with the routine methods for obtaining suitable biological isolate.
GATA-3 and Tbet are proteins which, as transcription factors, have their effect in the cell core of T helper cells of the subtype Th1 and Tlh2. In order to determine the concentration of these two nuclear proteins in a specified volume of a biological isolate, as in a specified volume of whole blood or the like, cells which form GATA-3 and Tbet must first be isolated and subsequently lyzed. A direct confirmation of these proteins from human serum or plasma is hardly possible, since they are not available there in detectable concentration. An analysis of GATA-3 and Tbet therefore takes place if necessary in four stages:
    • Partitioning and isolation of the GATA-3/Tbet expressing cells from the other cellular components of the whole blood
    • Disruption of the cells and release of the intracellular/nuclear proteins
    • Measurement of the concentration of GATA-3 and Tbet and
    • Standardization of the found concentrations of GATA-3 and Tbet.
According to an advantageous development, regardless of whether the expression level of GATA-3 and/or Tbet is determined via the protein or mRNA quantity, the inventive method comprises also one or more of the following steps:
    • (i) Isolation of leukocytes, preferably by means of Ficoll gradient centrifugation;
    • (ii) Enrichment of leukocytes, preferably by means of size exclusion filtration or
    • (iii) Enrichment of Th1/Th2 cells in particular CD4+ T cells with the help of cell-specific antibodies which are preferably coupled to magnetic beads.
The mentioned steps (i)-(iii) are performed prior to the cell disruption and in each case facilitate an increase in the sensitivity as well as predictability of the diagnostic method, since, in particular in the leukocytes the genes GATA-3 and Tbet are differentially expressed.
According to a further aspect of the present invention an assignment of the patient to a molecular phenotype of the subgroup “Th2 high” occurs when at least one of the following conditions is fulfilled:
    • a) The GATA-3 gene expression in the biological isolate is higher than a defined reference value
    • b) The ratio of GATA-3:Tbet gene expression in the biological isolate is higher than a defined reference value.
The subgroup “Th2 high” is thus characterized either by a high absolute GATA-3 gene expression in comparison to a defined reference value. In the process,—in the case of the measurement of the protein quantity—a corresponding value of the GATA-3 protein content in the isolate of a healthy person can be used as a reference value. However, absolute reference values can also be used. In the case of the measurement of the mRNA quantity a corresponding value of the GATA-3 mRNA quantity in the isolate of a healthy person can be used as a reference value. However, on the other hand, absolute reference values such as for example copies/ml can also be used.
An assignment of the patient to the mentioned molecular phenotype of the subgroup “Th2 high” takes place according to an advantageous embodiment of the inventive method when as an alternative to or in addition to the increased GATA-3 gene expression the ratio of GATA-3:Tbet gene expression in the biological isolate is higher than a defined reference value. In the process a corresponding value of the ratio of GATA-3:Tbet gene expression in the isolate of a healthy person is used. The determination of the ratio of GATA-3:Tbet gene expression increases the certainty of the statement, since in the process along with the GATA-3 gene expression the Tbet gene expression is established as an additional parameter. Since the two transcription factors mutually regulate one another in their expression, as initially described, the inclusion of Tbet constitutes an internal control for the measurement of the GATA-3 gene expression.
According to one advantageous development, the inventive method for assigning the patient to the molecular phenotype of the subgroup “Th2 high” comprises the steps:
    • Release of proteins or RNA from cells of a biological isolate of the patient;
    • Determination of the expression level of the proteins or of the mRNA for GATA-3 and/or Tbet;
    • Placement of the patient in the subgroup “Th2 high” when at least one of the foregoing conditions mentioned under a) or b) apply.
As an alternative, in addition to the mentioned determination of the GATA-3 and/or Tbet gene expression, a determination of further parameters for certain placement/classification in the subgroup “Th2 high” can take place. Thus, for example the serum IgE level and the number of eosinophilic granulocytes can be measured. An assignment to the subgroup “Th2 high” takes place additionally whenever the serum IgE level is higher than 100 IU/ml and/or the number of the eosinophilic granulocytes is 0.14×109 cells per liter or higher. As an alternative, if required, the concentration in nitric oxide in the exhaled air, thus a determination of the FeNO value can be performed.
Another advantageous embodiment of the inventive method relates to an assignment of the patient to a molecular phenotype of the subgroup “Th2 low” when at least one of the following conditions is fulfilled:
    • a) The GATA-3 gene expression in the biological isolate is lower than a defined reference value,
    • b) The ratio of GATA-3:Tbet gene expression in the biological isolate is lower than a defined reference value.
The subgroup “Th2 low” is thus characterized either by a low absolute GATA-3 gene expression in comparison to a defined reference value. In the case of the measurement of the protein quantity, in the process, a corresponding value of the GATA-3 protein content in the isolate of a healthy person can be used as a reference value. Here it should be noted that in the case of a patient of the subgroup “Th2 low” with an illness accompanied by chronic inflammations the absolute GATA-3 gene expression will regularly be higher than in an isolate of a healthy patient. However, the absolute GATA-3 gene expression can also be lower than in the case of a healthy person. In any case, the GATA-3 gene expression is also not as high as described for the subgroup “Th2 high”. Consequently, an assignment of the patient to the subgroup “Th2 low” occurs when said patient's GATA-3 protein content in comparison to an isolate of a healthy person, if at all, is only moderately increased. However, fixed reference values can also be used. In the case of the measurement of the mRNA quantity, a corresponding value of the GATA-3 mRNA quantity in the isolate of a healthy person can be used as a reference value, wherein an assignment of the patient to the subgroup “Th2 low” takes place when said patient's GATA-3 mRNA quantity is lower than in a corresponding sample of a healthy person or in any event is not significantly increased. However, on the other hand fixed reference values can be used.
An assignment of the patient to the mentioned molecular phenotype of the subgroup “Th2 low” takes place according to one advantageous embodiment of the inventive method, when as an alternative to or in addition to the decreased lower GATA-3 gene expression, the ratio of GATA-3:Tbet gene expression in the biological isolate is lower than a defined reference value. In the process a corresponding value of the ratio of GATA-3:Tbet gene expression in the isolate of a healthy person can be used as a reference value. The determination of the ratio of GATA-3:Tbet gene expression also increases the certainty of the statement in this case, since in the process along with GATA-3 gene expression as an additional parameter the Tbet gene expression is determined. Since the two transcription factors mutually regulate one another in their expression, as initially described, the inclusion of Tbet constitutes an internal control for the measurement of the GATA-3 gene expression.
According to one advantageous further development the inventive method for assigning the patient to the molecular phenotype of the subgroup “Th2 low” comprises the steps:
    • Release of proteins or RNA from cells of a biological isolate of the patient;
    • Determination of the expression level of the proteins or of the mRNA for GATA-3 and/or Tbet;
    • Placement of the patient in the subgroup “Th2 low” when at least one of the foregoing conditions mentioned under a) or b) apply.
As an alternative, in addition to the mentioned determination of the GATA-3 and/or Tbet gene expression, in turn a determination of further parameters for certain placement in the subgroup “Th2 low” can take place. Thus, for example the serum IgE level and the number of eosinophilic granulocytes can be measured. An assignment to the subgroup “Th2 low” takes place additionally whenever the serum IgE level is lower than 100 IU/ml and/or the number of the eosinophilic granulocytes is below 0.14×109 cells per liter. As an alternative, if required, the concentration in nitric oxide in the exhaled air, thus a determination of the FeNO value can be performed.
According to another advantageous embodiment, an assignment of the patient to a molecular phenotype of the subgroup “Th1 high” occurs when at least one of the following conditions is fulfilled:
    • a) The Tbet gene expression in the biological isolate is higher than a defined reference value,
    • b) The ratio of Tbet:GATA-3 gene expression in the biological isolate is higher than a defined reference value.
The subgroup “Th1 high” is thus characterized either by a high absolute Tbet gene expression in comparison to a defined reference value. In the case of the measurement of the protein quantity, in the process, a corresponding value of the Tbet protein content in the isolate of a healthy person can be used as a reference value, wherein an assignment of the patient to the subgroup “Th1 high” takes place when said patient's Tbet protein content is increased. However, fixed reference values can also be used. In the case of the measurement of the mRNA quantity, a corresponding value of the Tbet mRNA quantity in the isolate of a healthy person can be used as a reference value, wherein an assignment of the patient to the subgroup “Th1 high” takes place when said patient's Tbet mRNA quantity is increased. However, on the other hand, fixed reference values can also be used.
An assignment of the patient to the mentioned molecular phenotype of the subgroup “Th1 high” takes place according to one advantageous embodiment of the inventive method, when as an alternative to or in addition to the decreased Tbet gene expression, the ratio of Tbet:GATA-3 gene expression in the biological isolate is higher than a defined reference value. In the process a corresponding value of the ratio of Tbet:GATA-3 gene expression in the isolate of a healthy person can be used as a reference value. The determination of the ratio of Tbet:GATA-3 gene expression also increases the certainty of the statement in this case, since in the process along with the Tbet gene expression as an additional parameter the GATA-3 gene expression is determined and the inclusion of GATA-3 constitutes an internal control for the measurement of the Tbet gene expression.
According to one advantageous development, the inventive method for assigning the patient to the molecular phenotype of the subgroup “Th1 high” comprises the steps:
    • Release of proteins or RNA from cells of a biological isolate of the patient;
    • Determination of the expression level of the proteins or of the mRNA for Tbet and/or GATA-3;
    • Placement of the patient in the subgroup “Th1 high” when at least one of the foregoing conditions mentioned under a) or b) apply.
A further aspect of the present invention relates to a method that facilitates an assignment of the patient to a molecular phenotype of a subgroup “Th1 low” when at least one of the following conditions is fulfilled:
    • a) The Tbet gene expression in the biological isolate is lower than a defined reference value,
    • b) The ratio of Tbet:GATA-3 gene expression in the biological isolate is lower than a defined reference value.
The subgroup “Th1 low” is thus characterized either by a low absolute Tbet gene expression in comparison to a defined reference value. In the case of the measurement of the protein quantity, in the process, a corresponding value of the Tbet protein content in the isolate of a healthy person can be used as a reference value. Here it should be noted that in the case of a patient of the subgroup “Th1 low” with an illness accompanied by chronic inflammations the absolute Tbet gene expression can however be higher than in an isolate of a healthy person. However, the absolute Tbet gene expression can also be lower than in the case of a healthy person. In any event, the Tbet gene expression is not as high as described for the subgroup “Th1 high”. Hence, an assignment of the patient to the subgroup “Th1 low” takes place when said patient's Tbet protein content in comparison to an isolate of a healthy person, if at all, is increased, however not significantly. However, fixed reference values can also be used. In the case of the measurement of the mRNA quantity, a corresponding value of the Tbet mRNA quantity in the isolate of a healthy person can be used as a reference value, wherein an assignment of the patient to the subgroup “Th1 low” takes place when said patient's Tbet mRNA quantity is lower than in the corresponding sample of a healthy patient or in any event is not significantly increased. However, on the other hand, fixed reference values can also be used.
An assignment of the patient to the mentioned molecular phenotype of the subgroup “Th1 low” takes place according to one advantageous embodiment of the inventive method, when as an alternative to or in addition to the decreased Tbet gene expression, the ratio of Tbet:GATA-3 gene expression in the biological isolate is lower than a defined reference value. In the process a corresponding value of the ratio of Tbet:GATA-3 gene expression in the isolate of a healthy person can be used as a reference value. The determination of the ratio of Tbet:GATA-3 gene expression also increases the certainty of the statement in this case, since in the process along with the Tbet gene expression as an additional parameter the GATA-3 gene expression is determined and the inclusion of GATA-3 constitutes in a certain sense an internal control for the measurement of the Tbet gene expression.
According to one advantageous development, the inventive method for assigning the patient to the molecular phenotype of the subgroup “Th1 low” comprises the steps:
    • Release of proteins or RNA from cells of a biological isolate of the patient;
    • Determination of the expression level of the proteins or of the mRNA for Tbet and/or GATA-3;
    • Placement of the patient in the subgroup “Th1 low” when at least one of the foregoing conditions mentioned under a) or b) apply.
As an alternative, in addition to the mentioned determination of the GATA-3 and/or Tbet gene expression, in turn a determination of further parameters for certain placement in the subgroup “Th1 high” and “Th1 low” can take place. Thus, for example the number of eosinophilic granulocytes or the serum IgE level can be measured. An assignment to the subgroup “Th1 high” takes place when the serum IgE level is lower than 100 IU/ml and/or the number of the eosinophilic granulocytes is below 0.14×109 cells per liter. Otherwise, an assignment to the subgroup “Th1 low” takes place. As an alternative, if required, the concentration in nitric oxide in the exhaled air, thus a determination of the FeNO value can be performed.
In order to consider differences in sample preparation, a standardization of the concentrations of GATA-3 and Tbet can be performed. Differences in the sample preparation can for example come about through differing cell numbers that are lyzed, through differing lysis efficiencies of the individual samples or through differing content in the various cell types within the cell preparations. In accordance with the invention, possibilities for standardization include the following: Standardization to the total protein content of the cell lysate, standardization to the cell number that has been lyzed or standardization to the concentration of specific marker proteins that are specifically found in specified cell types.
The patients with the diagnosed molecular phenotype of the subgroup “Th2 high” can under circumstances simultaneously be placed in the subgroup “Th1 low”. Also, patients with the diagnosed molecular phenotype of the subgroup “Th1 high” can under circumstances simultaneously be placed in the subgroup “Th2 low”. This is to be attributed to the fact represented above that the polarization to Th2 inhibits a Th1 differentiation through suppression of Tbet and vice versa.
Within the scope of the present invention, illnesses are diagnosed or treated that are accompanied by chronic inflammations, such as autoimmune diseases and diseases from the area of rheumatic diseases (manifestations among others on the skin, lungs, kidneys, vascular system, nervous system, connective tissue, locomotor system, endocrine system), immediate-type allergic reactions and asthma, chronic obstructive lung diseases (COPD), arteriosclerosis, psoriasis and contact eczema as well as chronic rejection reactions after organ and bone marrow transplants. Also tumor diseases can be diagnosed and treated in accordance with the invention, provided GATA-3 or Tbet are involved in the development and/or deregulated as after-effects.
Within the scope of the present invention, the chronic inflammatory disease is either Th2-induced, such as for example allergic bronchial asthma, rhinoconjunctivitis, allergic sinusitis, atopical dermatitis, food allergies, pemphigus, ulcerative colitis, parasitic illnesses, or Th1-induced, such as for example psoriasis, allergic contact eczema, Crohn's disease, COPD, rheumatoid arthritis, autoimmune diseases, type 1 diabetes mellitus or MS.
The aforementioned problem is additionally solved in accordance with the invention through a medicament for the treatment of illnesses of a human patient with a molecular phenotype that are accompanied by chronic inflammations, wherein the molecular phenotype has been determined in accordance with one or more embodiments of the mentioned inventive diagnostic method. The identified molecular phenotype comprises in the process in particular the groups “Th1 low, “Th1 high”, “Th2 low” or “Th2 high”.
According to one preferred embodiment the mentioned medicament contains a specific ribonucleic acid or deoxyribonucleic acid specific for GATA-3 or Tbet, in particular a DNAzyme specific for GATA-3 or Tbet.
The “10-23” model represents a general DNAzyme model (Sontoro et al., 1997). DNAzymes of the 10-23 model—also referred to as “10-23 DNAzymes” have a catalytic domain of 15 nucleotides, which are flanked by two substrate binding domains. The catalytic domain in the process preferably has the sequence ggctagctacaacga (SEQ ID No. 154). The length of the substrate binding domains is variable: they are either of equal length or variable in length. In one preferred design, the length of the substrate binding domains ranges between 6 and 14 nucleotides, very especially preferably in each case at least nine nucleotides. Such DNAzymes comprise the general sequence nnnnnnnnnggctagctacaacgannnnnnnnn (SEQ ID NO 155). Especially preferable in the process are substrate binding domains that bind the mRNA, coding for the proteins GATA-3 and Tbet.
The specified catalytic central domain ggctagctacaacga is only one preferred embodiment. A person skilled in the art is aware of the fact that “10-23 DNAzymes” can be obtained with comparable biological activity with a modified catalytic domain.
In one especially preferred embodiment, the substrate binding domains are completely complementary to the region that flanks the cleaving site. However, in order to bind the target RNA and cleave it, the DNAzyme does not necessarily have to be completely complementary. DNAzymes of the 10-23 type cleave the target mRNA on purine-pyrimidine sequences. Within the scope of the present invention the DNAzymes preferably comprise the in vivo active DNAzymes against GATA-3 and Tbet in accordance with WO 2005/033314 A2, whose content is incorporated as disclosure content of the present invention.
A medicament for specific inhibition of the GATA-3 expression in vivo contains in particular at least one DNAzyme selected from the group consisting of DNAzymes with a sequence in accordance with one of the sequences SEQ ID NO 1 through SEQ ID NO 70. Such a DNAzyme binds preferably on an mRNA which codes for a human GATA-3 gene with a gene sequence selected from the sequences SEQ ID NO 151 (human GATA-3 from database no.: XM_043124), SEQ ID NO 152 (human GATA-3 from Database No.: X58072) and SEQ ID NO 153 (human GATA-3, sequenced from plasmid pCR2.1).
A medicament for specific inhibition of the GATA-3 expression in vivo preferably contains the DNAzyme hgd40 with the sequence 5′-GTGGATGGAggctagctacaacgaGTCTTGGAG (SEQ ID NO 40).
A medicament for specific inhibition of the Tbet expression in vivo contains in particular at least one DNAzyme selected from the group consisting of DNAzymes with a sequence according to one of the sequences SEQ ID NO 71 through SEQ ID NO 148. Such a DNAzyme preferably binds on an mRNA which codes for a human Tbet gene with a gene sequence selected from the sequences SEQ ID NO 149 (human Tbet from the Database No.: NM_013351) and SEQ ID NO 150 (human Tbet sequenced from pBluescript-SK).
A medicament for specific inhibition of the Tbet expression in vivo contains preferably the DNAzyme td69 with the sequence 5′-GGCAATGAAggctagctaccaacgaTGGGTTTCT (SEQ ID NO 139) or td70 with the sequence 5′-TCACGGCAAggctagctacaacgaGAACTGGGT (SEQ ID No 140).
As an alternative to the DNAzymes the medicament for specific inhibition of the GATA-3 or Tbet expression can contain a suitable siRNA.
The medicament preferably has a formulation with which the mentioned specific ribonucleic acid or deoxyribonucleic acid molecules can be administered to the patient in the form of a pharmaceutically acceptable composition either orally, rectally, parenterally, intravenously, intramuscularly or subcutaneously, intracisternally, intravaginally, intraperitoneally, intrathecally, intravascularly, locally (powder, ointment or drops) or in the form of a spray. For the local administration of the medicament of this invention include ointments, powders, sprays or inhalants. The active component is mixed under sterile conditions with a physiologically acceptable excipient and possible preservatives, buffers or propellants, depending on requirements.
The medicament can be used for therapy for all diseases that are accompanied by chronic inflammations.
According to an especially preferred design of the present invention, the treatment of the patients takes place with a molecular phenotype of the subgroup “Th2 high” with a GATA-3 specific DNAzyme. The therapy of a patient with a molecular phenotype of the subgroup “Th1 high” takes place with a Tbet specific DNAzyme. In addition, the treatment of a patient with the molecular phenotype of the subgroup “Th2 low” can take place with a Tbet specific DNAzyme and the treatment of a patient with the molecular phenotype of the subgroup “Th1 low” can occur with a GATA-3 DNAzyme.
An inventive medicament with a GATA-3 specific DNAzyme is thus provided preferably for the treatment of a patient with the molecular phenotype of the subgroup “Th2 high” and a medicament with a Tbet specific DNAzyme is preferably provided for the treatment of a patient with the molecular phenotype of the subgroup “Th1 high”.
In accordance with the invention, one special advantage of the medicament according to an embodiment mentioned above for the specific therapy of an inventively diagnosed subgroup of patients—namely “Th2 high”, “Th2 low”, “Th1 high” or “Th1 low” lies in the fact that with the help of the specific medicament, in particular of a DNAzyme and/or an siRNA, a functional inactivation of the coding ribonucleic acid molecules of transcription factors takes place, whose differential expression was determined beforehand and which is involved in the development of the chronic inflammatory reactions and autoimmune diseases. This strategy differs distinctly from conventional approaches and also differs from the approach according to Corren et al., 2011, since there, one the one hand for example the quantity of periostin (surrogate marker) is measured, but then a therapy aimed at another target, such as for example IL-13 with the help of an anti-IL13 antibody was proposed. The inventive medicament on the other hand has a high specificity. It causes a cell-specific intervention and is specific for compartments and organs.
Dosage forms of the inventive medicament comprise pharmaceutically acceptable compositions which contain modifications and “prodrugs”, provided they do not trigger excessive toxicity, irritations or allergic reactions in patients according to reliable medical assessment. The term “prodrug” relates to compounds that are transformed for improvement of the absorption, such as for example through hydrolysis in the blood.
The inventive medicament can also be used in the form of a multiple emulsion for application of the mentioned specific nucleic acid molecules. A suitable multiple emulsion to this end comprises an exterior water phase W1, an oil phase O dispersed in the exterior water phase W1 and an interior water phase W2 dispersed in the oil phase O, wherein in the interior water phase W2 at least one electrolyte selected from the group of alkali metal halides and earth alkali metal halides and sulfates and at least one specific ribonucleic acid or deoxyribonucleic acid molecule, preferably a DNAzyme specific for GATA-3 or Tbet is provided, wherein the exterior water phase W1 contains a hydrophilic emulsifier which is a polymer of ethylene oxide and propylene oxide, and the oil phase O is formed by triacylglycerides and has a lipophilic emulsifier from the group of dimethicones. With the help of such multiple emulsion in particular nucleic acid molecules can be especially effectively protected from undesirable decomposition.
The type of dosage will be determined by the attending physician in accordance with the clinical factors. A person skilled in the art is aware of the fact that the type of dosage is dependent on different factors such as e.g. body size, weight, body surface, age, sex or the general health of the patient, but also depends on the agent to be administered, the duration and type of administration and on other medicaments that may be administered in parallel. In the process, according to an especially advantageous embodiment, the quantity of the active ingredient of the medicament can be adapted to the measured expression level. Thus, in the case of placement in the subgroup “Th2 high” and an established very high GATA-3 gene expression an increase dose of the active ingredient, in particular a DNAzyme specific for GATA-3 specific can be administered. Correspondingly, in the case of placement in the subgroup “Th1 high” and an established very high Tbet gene expression an increased dose of the active ingredient, in particular of a DNAzyme specific for Tbet can be administered.
A further aspect of the present invention relates to a kit for diagnosing a molecular phenotype of a human patient suffering from an illness accompanied by chronic inflammation, wherein the kit contains at least one specific component for quantitative determination of the protein or mRNA quantity of GATA-3 and/or Tbet in a biological isolate of the patient.
The inventive kit for diagnosis can be easily offered in the form of a ready to use “kit” which comprises antibodies or antigens that are adsorbed on a surface of a carrier and a preparation of human IgG antibodies which e.g. in the case of a human, a preparation of anti-human IgG antibodies that are marked such that they are proved by a cascade of reactions of the type biotin-streptavidin peroxidase or alkaline phosphatase.
As an alternative, the kit for diagnosis also comprises, in addition to a carrier, buffers and reagents, e.g. reagents which are necessary for proof of the reaction such as e.g. streptavidin that is coupled to a marker that gives a color reaction.
As an alternative, the kit additionally comprises a standard sample of GATA-3 and/or Tbet for calibration of the kit, wherein for proof of the protein or mRNA of GATA-3 and/or Tbet, a standard sample is used.
In the case of one preferred embodiment, a specific antibody against GATA-3 and/or Tbet is included for the quantitative determination of the protein quantity. If necessary, in accordance with a modification, further components for execution of an immunoassay, in particular an ELISA, can be included.
The further component for carrying out the ELISA is selected from the group consisting of lysis buffers for cell disruption, a microwell plate, protein quantity standards for GATA-3 and/or Tbet, secondary antibodies and a coupled enzyme for implementation of a substrate for detection. Preferably, in addition to a first specific antibody against GATA-3 and/or Tbet the kit comprises a further specific antibody against GATA-3 or Tbet.
The kit can contain a sequence specific probe and/or primer for the GATA-3 and/or Tbet genes for quantitative determination of the mRNA quantity.
BRIEF DESCRIPTION OF THE DRAWINGS
Further features, details and advantages of the invention arise from the wording of the claims as well as from the following description of exemplary embodiments with the assistance of the drawings. The figures show the following:
FIG. 1 shows the influence of various detergents on the release of GATA-3 from stimulated Jurkat cells,
FIGS. 2a,b show results of a quantification of Tbet and GATA-3 by means of chromogenic sandwich ELISA,
FIG. 3 shows a standard curve of a GATA-3 ELISA for quantification of samples
FIG. 4 shows a standard curve of a Tbet ELISA for quantification of samples
FIG. 5 shows a standardized determination of Tbet in lysates of human peripheral mononuclear cells (PBMC)
FIG. 6 shows a significant improvement of allergic airway inflammation after four-day treatment with the GATA-3 specific DNAzyme hgd40 (SEQ ID NO 40) compared to untreated mice,
FIG. 7 shows the influence of the GATA-3 specific DNAzyme hgd40 (SEQ ID NO 40) on the number of neutrophils occurring in the chronic inflammation, the number of eosinophils in the BAL and the release of IL-5 after an eight-week treatment and
FIG. 8 shows the influence of the GATA-3 specific DNAzyme hgd40 (SEQ ID NO 40) on the peribronchial/perivascular inflammation and goblet cell hyperplasia in the lung tissue.
 DETAILED DESCRIPTION OF THE INVENTION
Material and Methods:
Cells can be isolated, for example, by means of technologies based on the binding of specific antibodies. Magnetic beads, which can be obtained from the firms Miltenyi (Macs-System), Dynal (DynaBeads) or BD-Bioscience (iMAG), are used. As an alternative this happens via a cell purification by means of fluorescent marked antibodies on cell sorters for example from the firm Cytomation (MOFLO) or BD-Bioscience (FACS-Vantage). The purity of the target cells is preferably at least 80%, more strongly preferred at least 95% and most preferred at least 99%.
Methods for the isolation of RNA are e.g. described in Sambrook and Russell, Molecular Cloning, A Laboratory Manual, 3rd Edition, Cold Spring Harbor Laboratory (2001), New York and Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons (1998), New York. In addition it is possible for the average person skilled in the art to use commercially available kits (Silika-Technologie) e.g. the RNeasy Kit from the firm Qiagen, for RNA isolation. In addition it is preferable to purify mRNA directly from the target cells by using commercial kits for example from the firm Qiagen (Oligotex mRNA Kit), Promega (PolyATract mRNA Isolation System) or Miltenyi (mRNAdirect).
EXEMPLARY EMBODIMENTS Exemplary Embodiment 1
GATA-3 and Tbet are proteins that, as transcription factors, have their effect in the cell core of T helper cells of the subtype Th1 and Th2. In order to determine the concentration of these two nuclear proteins in a specified volume of a biological isolate in particular in a specified volume of whole blood, cells which form GATA-3 and Tbet must first be isolated and subsequently lyzed. A direct proof of these proteins from human serum or plasma is not possible, since they are not present there in detectable concentration. An analysis of GATA-3 and Tbet therefore takes place in 4 stages:
    • Partitioning and isolation of the GATA-3/Tbet expressing cells from the other cellular components of the whole blood
    • Disruption of the cells and release of the intracellular/nuclear proteins
    • Measurement of the concentration of GATA-3 and Tbet and
    • Standardization of the found concentrations of GATA-3 and Tbet.
      Partitioning and Isolation of the GATA-3/Tbet Expressing Cells from the Other Cellular Components of the Whole Blood
This can be performed by different methods of variable complexity, in particular the following steps for partitioning and isolation within the scope of the present invention:
    • An isolation of leukocytes from whole blood by means of Ficcoll density gradient centrifugation with subsequent affinity purification of the Th1/Th2 cell types by antibodies against specific surface markers,
    • If necessary, the affinity purification of the Th1/Th2 cell types by antibodies against specific surface markers can also be performed as a 1-stage method without prior enrichment of the leukocytes,
    • If necessary, the isolation of leukocytes through Ficoll density gradient centrifugation from whole blood suffices in order to perform a quantification of the proteins GATA-3 and Tbet,
    • If necessary, in place of the Ficoll density gradient centrifugation a bead-based affinity purification of the Th1/Th2 cell types through antibodies against specific surface markers in a deep-well plate in the 96 well format can be employed,
    • If required, in place of the Ficoll density gradient centrifugation a bead-based affinity purification of the leukocytes through antibodies against specific surface markers in a deep-well plate in the 96 well format can be employed,
    • If necessary, a hypoosmolar lysis of the erythrocytes can take place to obtain a leukocyte preparation or
    • If necessary the protein disruption can occur directly from the whole blood
      Disruption of the Cells and Release of the Intracellular/Nuclear Proteins
This can be achieved through various methods and principles, in particular within the scope of the present invention the following procedural steps:
    • Destruction of cellular membranes through lysis buffers with different principles of operation:
      • a) Hypotonic buffers which induce a bursting of the cells
      • b) Buffers containing detergents, which destroy the cell membrane and as a result, release intracellular proteins
      • c) Buffers of high ionic strength or osmotically active buffers which remove water from the cells and as a result destroy the cell integrity
    • Physical methods such as heating up, shock freezing or ultrasound
    • Mechanical methods such as homogenizing or grinding.
Examples of buffers containing detergents could be:
    • Buffer systems with a high concentration of ionic (e.g. SDS or cholate and its derivatives) or non-ionic (e.g. triton or Tween-20) detergents
    • Mixtures of ionic and non-ionic detergents (e.g. Ripa buffers with 50 mM Tris⋅HCI (pH 7.5), 150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate and 0.1% SDS)
    • Commercially available lysis buffers with unknown composition (e.g. M-PER)
      The influence of different detergents on the release of GATA-3 from stimulated Jurkat cells is illustrated in FIG. 1. The lysis of Jurkat cells (human T cell line) through various lysis buffers and quantification of GATA-3 by means of ELISA resulted in an especially high release of GATA-3 protein in the case of the use of the RIPA buffer (1% RIPA). About 50 ng/ml of GATA-3 were verified.
      Measurement of the Concentration of GATA-3 and Tbet
In principle, the concentration of the two transcription factors GATA-3 and Tbet can be determined with different methods. Within the scope of the present invention, among others there are:
    • ELISA (enzyme linked immunosorbent assay)
    • CLIA (chemoluminescence linked immunosorbent assay)
    • FLIA (fluorescence linked immunosorbent assay)
    • Mass spectrometric methods
    • Chromatographic methods (e.g. gas chromatography)
    • Fluid-based methods with solid phase separation, (e.g. HPLC)
    • Microfluidic and nanofluidic methods
FIG. 2a and FIG. 2b show the results of a quantification of Tbet and GATA-3 by means of chromogenic sandwich ELISA. The cells were obtained from whole blood through Ficoll density gradient centrifugation. The cells (stimulated human mononuclear cells) were lyzed with a Ripa buffer. The lysate was examined with two ELISA prototype methods with respect to the concentration of GATA-3 and Tbet. The concentration of the two proteins was depicted with respect to the total protein concentration of the cell lysates (standardization to protein content).
The results in accordance with FIG. 2a show that Th1 cells have a higher content of Tbet (circa 160 ng/ml analyte/mg protein) than Th2 cells (circa 56 ng/ml analyte/mg protein) and this fact can be clearly confirmed from the results of the ELISA test:
Ng/ml Tbet/mg
Cells Protein
Th2 B11-14 51.01
Th2 B11-15 58.40
Th2 B11-16 50.24
Th2 B11-17 68.79
Th2 B11-19 49.63
Th2 B11-20 55.85
Mean 55.65
STABW 7.31
VK(%) 13.14
Th1 B11-14 202.24
Th1 B11-19 106.34
Th1 B11-20 167.46
Mean 158.68
STABW 48.55
VK(%) 30.59
The Tbet content in the Th1 cells is thus more than two times greater, namely by a factor of about three, than in the Th2 cells.
According to FIG. 2b the content in GATA-3 in the Th2 cells (circa 10 ng/ml analyte/mg protein) is higher than in Th1 cells (circa 6 ng/ml analyte/mg protein) The GATA-3 content is more than 1.5 times higher in the Th2 cells here—namely by a factor of about 1.7—than in Th1 cells.
In addition, one can see from FIGS. 2a and 2b that in the case of standardization to the protein content the quantity ratio of Tbet:GATA-3 in Th1 cells differs significantly form the corresponding ratio in Th2 cells. Thus the quantity ratio of Tbet:GATA-3 here in Th1 cells is about 27, thus more than 20, while the corresponding quantity ratio in Th2 cells is circa 6, thus less than 10.
The quantitative determination of GATA-3 and Tbet occurs in each case by means of a sandwich ELISA (Enzyme linked immune sorbent assay).
Exemplary Embodiment 2—GATA-3 ELISA
To this end, the wells of a 96 well microwell plate are coated with specific antibodies against GATA-3. After addition of the sample or of a standard, GATA-3 binds on the antibodies on the 96 well plate. After a wash step to remove the non-bound substances a second, specific biotinylated antibody against GATA-3 is added. After an additional wash step to remove the non-bound substances peroxidase marked streptavidin is added. After a last wash step to remove the non-bound substances substrate is added. The color development is terminated after a defined time by adding a stop solution. The intensity of the color development is quantified by a microwell plate reader. The quantification of the samples occurs by a comparison to the included standards of known protein concentration. FIG. 3 shows a corresponding standard curve of a GATA-3 ELISA.
According to the exemplary embodiment for the performance of the GATA-3 ELISA, the steps relate to the following in detail:
    • Insert number of required wells into a frame of the 96 well plate
    • Addition of 50 μl/well assay buffer
    • Addition of 100 μl/well standard/control/sample
    • Incubation for 60 minutes on the shaker
    • Wash all wells 4× with 400 μl/well of wash buffer
    • Addition of 100 μl/well biotinylated anti-GATA-3 antibodies
    • Incubation for 60 minutes on the shaker
    • Wash all wells 4× with 400 μl/well of wash buffer
    • Addition of 100 μl/well peroxidase marked streptavidin
    • Incubation for 30 minutes on the shaker
    • Wash all wells 4× with 400 μl/well of wash buffer
    • Addition of 100 μl/well substrate
    • Incubation for 30 minutes
    • Stop reaction by addition of 100 μl stop solution
    • Measurement of optical density at 450 nm with a microwell plate reader
Exemplary Embodiment 3—Tbet ELISA
The verification of the Tbet protein is executed in accordance with the following test principle: The quantitative determination of Tbet occurs by means of a sandwich ELISA (Enzyme linked immuno sorbent assay). To this end the wells of a 96 well microwell plate are coated with specific antibodies against Tbet. After addition of the sample or of a standard, Tbet binds on the antibodies on the 96 well plate. After a wash step to remove the non-bound substances a second, specific antibody against Tbet is added. After an additional wash step to remove the non-bound substances a peroxidase marked antibody against the Tbet specific antibody is added. After a last wash step to remove the non-bound substances substrate is added. The color development is terminated after a defined time by adding a stop solution. The intensity of the color development is quantified by a microwell plate reader. The quantification of the samples occurs by a comparison to the included standards of known protein concentration. FIG. 4 shows a corresponding standard curve of a Tbet ELISA.
According to the exemplary embodiment for the performance of the Tbet ELISA the steps relate to the following in detail:
    • Insert number of required wells into a frame of the 96 well plate
    • Addition of 50 μl/well assay buffer
    • Addition of 100 μl/well standard/control/sample
    • Incubation for 60 minutes on the shaker
    • Wash all wells 4× with 400 μl/well of wash buffer
    • Addition of 100 μl/well anti-Tbet antibodies
    • Incubation for 60 minutes on the shaker
    • Wash all wells 4× with 400 μl/well of wash buffer
    • Addition of 100 μl/well peroxidase marked anti-Tbet specific antibodies
    • Incubation for 30 minutes on the shaker
    • Wash all wells 4× with 400 μl/well of wash buffer
    • Addition of 100 μl/well substrate
    • Incubation for 30 minutes
    • Stop reaction by addition of 100 μl stop solution
    • Measurement of optical density at 450 nm with a microwell plate reader
      Standardization of the Concentrations of GATA-3 and Tbet
In order to consider differences in the sample preparation, a standardization of the concentrations of GATA-3 and Tbet can be performed. Differences in the sample preparation can arise e.g. due to the following:
    • Differing cell numbers to be lyzed
    • Differing lysis efficiencies of the individual samples or
    • Differing content in the different cell types within the cell preparations.
Possibilities for standardization include the following:
    • Standardization to the total protein content of the cell lysate (see under “Measurement of the Concentrations of GATA-3 and Tbet”)
    • Standardization to the cell number being lyzed (see FIG. 5) or
    • Standardization to the concentration of specific marker proteins that are specifically found in specified cell types.
FIG. 5 shows a standardized determination of Tbet in lysates of human peripheral mononuclear cells (PBMC). In the process a lysis of PBMCs of healthy subjects and patients suffering from allergic illnesses, such as e.g. allergic bronchial asthma, rhinoconjunctivitis, allergic sinusitis, atopical dermatitis, food allergies takes place. The concentration of Tbet was standardized to the cell number in the lysates. The illness is Th2 dependent and consistently a slight concentration in Tbet (circa 12 ng/ml/1 million cells) for allergy sufferers was determined compared to healthy subjects (circa 27 ng/ml/1 million cells). The Tbet concentration was thus reduced in the case of allergy sufferers by more than a factor of 2 compared to healthy subjects. Consequently, an assignment of the patients to the molecular phenotype “Th1 low” is easily possible here, since the Tbet gene expression in the biological isolate is lower than a defined reference value, here the Tbet gene expression of healthy subjects.
Exemplary Embodiment 4
In modification of Examples 2 and 3, in accordance with Example 4 Th1/Th2 cells are enriched by means of magnetic beads coated with cell specific antibodies for the sample preparation. Subsequently the verification of GATA-3 occurred in accordance with the provision according to Example 2.
Exemplary Embodiment 5
In modification of Examples 2 and 3, in accordance with Example 4 leukocytes are enriched by means of size exclusion filtration for the sample preparation. Subsequently the verification of GATA-3 occurred in accordance with the provision according to Example 2.
Exemplary Embodiment 6
A GATA-3 specific DNAzyme shows therapeutic effects in the mouse model of the OVA induced allergic airway inflammation of the “Th2 high” phenotype.
In order to provide the best possible illustration of the clinical phenotype “Th2 high” in the mouse model BALB/c mice were sensitized with the model allergen ovalbumin (OVA) in the presence of the adjuvant AI(OH)3 on days 0, 14 and 21 through intraperitoneal injection. On days 24-26 the mice inhaled a 1% OVA aerosol in order to cause a Th2 dominated allergic inflammatory reaction in the lungs. On days 23-26 the GATA-3 specific DNAzyme hgd40 (SEQ ID NO 40), dissolved in PBS, was intranasally administered. In the process the Balb/c-mouse strain is characterized in that it generates preferentially strong Th2 responses. This is reinforced by the use of AL(OH)3 as an adjuvant, which distinctly supports the formation of Th2 dominated immune responses. The described mouse model is correspondingly characterized by a massive infiltration of eosinophils an Th2 cells in the airways accompanied by a hyperplasia of the mucus forming goblet cells with increased mucus production as well as the formation of an airway hyperresponsiveness. Immunologically, along with allergen specific Th2 cells, characterized by the production of the typical cytokines IL-4, IL-5 and IL-13, also OVA specific antibodies of the immune globulin classes IgE and IgG1 (in the mouse both Th2 dependent) were detectable. All these parameters are typical clinical features of a “Th2 high” phenotype (Wenzel et al., Am J Respir Crit Care Med. 199 Sep; 160(3):1001-8; Woodruff et al., 2009). In the process the reaction strength with respect to some parameters in the animal model were even more distinctly pronounced than in the clinical situation with human patients, e.g. eosinophilic granulocytes constitute circa 60-70% of all leukocytes in the bronchial alveolar lavage (BAL) in the mouse model, while already 3-5% of these cells in the sputum of patients indicates a Th2 dominated phenotype.
According to FIG. 6, after four-day treatment with the GATA-3 specific DNYzyme hgd40 (SEQ ID NO 40) compared to untreated mice, a significant improvement of the allergic airway inflammation was ascertained. Above all the number of eosinophils in the BAL was significantly reduced. In addition, the BAL concentrations of the characteristic cytokines for the phenotype “Th2 high”, IL-5 and IL-13, were able to be significantly reduced.
Exemplary Embodiment 7
A GATA-3 specific DNAzyme shows significant therapeutic effects in the chronic mouse model of a Th2 dominated allergic airway inflammation.
In order to provide the best possible illustration of the clinical phenotype “Th2 high” in the mouse model, BALB/c mice were sensitized with the model allergen ovalbumin (OVA) in the presence of the adjuvant AI(OH)3 on days 0, 14 and 21 through intraperitoneal injection. By means of twice weekly OVA aerosol provocations over a time period of 14 weeks a chronic inflammation of the airways was caused in the mice. During the last eight weeks therapy was provided three times a week (until day 121) either with budesonide or the GATA-3 specific DNAzyme hdg40 through intranasal application.
According to FIGS. 7 and 8 after eight weeks of treatment with GATA-3 specific DNAzyme hdg40 (SEQ ID NO 40) the number of eosinophils in the BAL was able to be significantly reduced and in addition a reduction of the number of neutrophils occurring in the chronic inflammation was also observed. This was accompanied by a lowered peribronchial/perivascular inflammation and reduced goblet cell hyperplasia. Simultaneously, in re-stimulated lymphocytes of those treated with hgd40 a reduced release of IL-5 was observed. In the budesonide group, on the other hand no significant improvement of the parameters cold be observed.
The invention is not restricted to one of the previously described embodiments, but rather can be modified in many respects.
All features and advantages arising from the claims, the description and the drawings, including design details, spatial arrangements and procedural steps can be essential to the invention both individually as well as in a variety of combinations.

Claims (5)

What is claimed:
1. A method for diagnosing and treating chronic inflammation in a patient suffering from an illness accompanied by chronic inflammation characterized by a dominance of T-cells of the Th1 subtype with increased expression of Tbet and Interferon gamma and/or increased Interferon gamma release, in combination with a relative absence of Th2-driven inflammatory features such as GATA-3 expression, expression and/or release of IL-4, IL-5 and IL-13 and accumulation of eosinophil granulocytes by identifying a molecular phenotype of the patient wherein the molecular phenotype is selected from the group consisting of the subgroups “Th1 high” and “Th1 low” and the gene expression of GATA-3 and/or Tbet is measured in a biological isolate of the patient and used for the assignment to a molecular phenotype of the illness wherein a therapeutic agent for downregulating Tbet expression is administered when the patient has a molecular phenotype of Th1 high and a therapeutic agent for downregulating the effects of GATA 3 is administered when the patient has a molecular phenotype of Th1 low.
2. The method according to claim 1, characterized in that
the expression level of GATA-3 and/or Tbet is determined via the protein or mRNA quantity, wherein the protein quantity is quantitatively determined with the help of an immunoassay, preferably an ELISA test, a radioimmunoassay, an electrochemiluminescence immunoassay, a CLIA (chemoluminescence-linked immunosorbent assay), an FLIA (fluorescence-linked immunosorbent assay) or a multiplex-assay; and/or
the expression level of GATA-3 and/or Tbet is determined via the protein or mRNA quantity, wherein the mRNA quantity is quantitatively determined in particular with the help of a PCR or a micro-array chip.
3. The method according to claim 1, characterized in that an assignment of the patient to a molecular phenotype of the subgroup “Th1 high” occurs when at least one of the following conditions is fulfilled:
the Tbet gene expression in the biological isolate is higher than a defined reference value,
the ratio of Tbet:GATA-3 gene expression in the biological isolate is higher than a defined reference value.
4. The method according to claim 1, characterized in that an assignment of the patient to a molecular phenotype of the subgroup “Th1 low” occurs when at least one of the following conditions is fulfilled:
the Tbet gene expression in the biological isolate is lower than a defined reference value,
the ratio of Tbet:GATA-3 gene expression in the biological isolate is lower than a defined reference value.
5. The method according to claim 1, characterized in that along with the determination of the gene expression of GATA-3 and/or Tbet a determination of the serum IgE level and/or the number of eosinophilic granulocytes occurs and/or the FeNO value is determined.
US15/782,595 2012-09-14 2017-10-12 Method for diagnosing a molecular phenotype of a patient suffering from an illness accompanied by chronic inflammation Active US10591489B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/782,595 US10591489B2 (en) 2012-09-14 2017-10-12 Method for diagnosing a molecular phenotype of a patient suffering from an illness accompanied by chronic inflammation

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP12184500.2 2012-09-14
EP12184500 2012-09-14
EP12184500.2A EP2708898A1 (en) 2012-09-14 2012-09-14 Method for diagnosing a molecular phenotype of a patient suffering from an illness related to chronic inflammation
PCT/EP2013/068317 WO2014040891A2 (en) 2012-09-14 2013-09-04 Method for diagnosing a molecular phenotype of a patient suffering from an illness accompanied by chronic inflammation
US201514428043A 2015-03-13 2015-03-13
US15/782,595 US10591489B2 (en) 2012-09-14 2017-10-12 Method for diagnosing a molecular phenotype of a patient suffering from an illness accompanied by chronic inflammation

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2013/068317 Continuation WO2014040891A2 (en) 2012-09-14 2013-09-04 Method for diagnosing a molecular phenotype of a patient suffering from an illness accompanied by chronic inflammation
US14/428,043 Continuation US9791454B2 (en) 2012-09-14 2013-09-04 Method for diagnosing a molecular phenotype of a patient suffering from an illness accompanied by chronic inflammation

Publications (2)

Publication Number Publication Date
US20180031571A1 US20180031571A1 (en) 2018-02-01
US10591489B2 true US10591489B2 (en) 2020-03-17

Family

ID=46963488

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/428,043 Active US9791454B2 (en) 2012-09-14 2013-09-04 Method for diagnosing a molecular phenotype of a patient suffering from an illness accompanied by chronic inflammation
US15/782,595 Active US10591489B2 (en) 2012-09-14 2017-10-12 Method for diagnosing a molecular phenotype of a patient suffering from an illness accompanied by chronic inflammation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US14/428,043 Active US9791454B2 (en) 2012-09-14 2013-09-04 Method for diagnosing a molecular phenotype of a patient suffering from an illness accompanied by chronic inflammation

Country Status (9)

Country Link
US (2) US9791454B2 (en)
EP (1) EP2708898A1 (en)
JP (2) JP6401163B2 (en)
KR (1) KR102157768B1 (en)
AU (2) AU2013314510A1 (en)
BR (1) BR112015005583A2 (en)
CA (2) CA2888860C (en)
RU (1) RU2672595C2 (en)
WO (1) WO2014040891A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3093022T3 (en) * 2015-05-15 2020-02-28 Sterna Biologicals Gmbh & Co. Kg Gata-3 inhibitors for use in the treatment of th2-driven asthma
WO2017205506A1 (en) 2016-05-24 2017-11-30 Emory University Particles with rna cleaving nucleobase polymers and uses for managing inflammatory disorders
EP3501607A1 (en) * 2017-12-22 2019-06-26 Sterna Biologicals GmbH & Co. KG Composition for the treatment of a patient suffering from a chronic inflammatory airway disease and manufacturing method and use of said composition
ES2973216T3 (en) * 2018-01-18 2024-06-19 Sterna Biologicals Gmbh Composition for the treatment of a patient suffering from ulcerative colitis and use of the composition as a medicine
EP3603617A1 (en) * 2018-07-30 2020-02-05 Sterna Biologicals GmbH & Co. KG Aerosol generating device for inhalatory administration of an antisense molecule containing composition

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033314A2 (en) 2003-10-02 2005-04-14 Philipps-Universität Marburg Method for the production of a cell and/or tissue and/or disease phase specific medicament
WO2008021532A2 (en) 2006-08-17 2008-02-21 University Of Chicago Treatment of inflammatory diseases
WO2009075822A1 (en) 2007-12-07 2009-06-18 Fibrogen, Inc. Methods for inhibiting t helper cell differentiation
WO2009124090A1 (en) 2008-03-31 2009-10-08 Genentech, Inc. Compositions and methods for treating and diagnosing asthma
WO2010107957A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20100285154A1 (en) 2005-01-07 2010-11-11 Newtree Industry Co., Ltd. Use of lignan compounds for treating or preventing inflammatory disease
EP2460880A1 (en) 2009-07-29 2012-06-06 Sysmex Corporation Marker and reagent for detection of human il-17-producing helper t cells, and method for detection of human il-17-producing helper t cells

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033314A2 (en) 2003-10-02 2005-04-14 Philipps-Universität Marburg Method for the production of a cell and/or tissue and/or disease phase specific medicament
US20100285154A1 (en) 2005-01-07 2010-11-11 Newtree Industry Co., Ltd. Use of lignan compounds for treating or preventing inflammatory disease
WO2008021532A2 (en) 2006-08-17 2008-02-21 University Of Chicago Treatment of inflammatory diseases
RU2440110C2 (en) 2006-08-17 2012-01-20 Юниверсити Оф Чикаго Therapy of inflammatory diseases
WO2009075822A1 (en) 2007-12-07 2009-06-18 Fibrogen, Inc. Methods for inhibiting t helper cell differentiation
WO2009124090A1 (en) 2008-03-31 2009-10-08 Genentech, Inc. Compositions and methods for treating and diagnosing asthma
WO2010107957A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2460880A1 (en) 2009-07-29 2012-06-06 Sysmex Corporation Marker and reagent for detection of human il-17-producing helper t cells, and method for detection of human il-17-producing helper t cells

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
Alter M., "Zur Regulation und Expression der Trankskriptionsfaktoren T-bet und Gata-3 bei allergish-entzundlichen Ekzemerkrankungen." Dissertation zur Erlangung des Doktorgrades der Medizin. Hannover, 2006, 119 p., p. 1, p. 13 par. 4, p. 15 par. 1, p. 26-27, p. 29-30, p. 33 par. 4, p. 36, p. 44-45, p. 49, p. 55 fig. 3, 15, p. 82 par. 2.
Chakir et al., T-bet/GATA-3 ratio as a measure of the Th1/Th2 cytokine profile in mixed cell populations: predominant role of GATA-3, Journal of Immunological Methods, pp. 157-169.
Corren et al., "Lebrikizumab Treatment in Adults with Asthma", The New England Journal of Medicine, pp. 1-11 (2011).
Das et al., "A critical role for NF-κB in Gata3 expression and T H2 differentiation in allergic airway inflammation", Nature Immunology, vol. 2, No. 1, pp. 45-50 (2001).
Ettreiki C. et al., "Effects of Iron on T-Bet/Gata3 Expression and Epigenetic Regulations in TH1 and TH2 Inflammatory Models", Inflammation Research, pp. S48-S49 (2011).
European Supplementary Search Report in European Application No. 12184500.2 dated May 14, 2013.
International Preliminary Report on Patentability in PCT/EP2013/068317 dated Mar. 17, 2015.
International Search Report in corresponding PCT/EP2013/068317 dated Dec. 18, 2013.
Nakamura et al., J. Allergy Clin Immunol, Feb. 1999: 215-222.
Office Action, Japanese patent application No. 2015-531519, dated Mar. 19, 2018. (English Translation).
Russian Office Action corresponding in Patent Application No. 2015112894 dated Sep. 1, 2017. (English Translation).
Russian Search Report corresponding in Patent Application No. 2015112894 dated Sep. 1, 2017.
Schena, Mark, et al. "Quantitative monitoring of gene expression patterns with a complementary DNA microarray." Science 270.5235 (1995): 467-470. *
Supplementary Appendix to Corren et al., "Lebrikizumab Treatment in Adults with Asthma", The New England Journal of Medicine, pp. 1-11 (2011).
Wenzel et al., "Evidence That Severe Asthma Can Be Divided Pathologically into Two Inflammatory Subtypes with Distinct Physiologic and Clinical Characteristics", Am J Respir Crit Care Med., vol. 160, pp. 1001-1008 (1999).
Woodruff et al., "Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids", PNAS, vol. 104, No. 40, pp. 15858-15863 (2007).
Woodruff et al., "T-helper Type 2-driven Inflammation Defines Major Subphenotypes of Asthma", Am J Respir Crit Care Med, vol. 180, pp. 388-395 (2009).
Zhang et al., J. Allergy Clin. Immunol., Nov. 2008: 961-968.

Also Published As

Publication number Publication date
CA2888860A1 (en) 2014-03-20
CA2888860C (en) 2023-07-18
CA3199111A1 (en) 2014-03-20
KR102157768B1 (en) 2020-09-21
JP6401163B2 (en) 2018-10-03
KR20150064084A (en) 2015-06-10
US20150260728A1 (en) 2015-09-17
JP2015531482A (en) 2015-11-02
WO2014040891A3 (en) 2014-05-30
JP2019007977A (en) 2019-01-17
JP6662969B2 (en) 2020-03-11
WO2014040891A2 (en) 2014-03-20
AU2013314510A1 (en) 2015-04-09
BR112015005583A2 (en) 2017-08-08
US20180031571A1 (en) 2018-02-01
US9791454B2 (en) 2017-10-17
AU2019204108B2 (en) 2021-11-25
RU2672595C2 (en) 2018-11-16
AU2019204108A1 (en) 2019-07-04
RU2015112894A (en) 2016-11-10
EP2708898A1 (en) 2014-03-19

Similar Documents

Publication Publication Date Title
US10591489B2 (en) Method for diagnosing a molecular phenotype of a patient suffering from an illness accompanied by chronic inflammation
AU2017228502C1 (en) Microbial consortium and uses thereof
Wang et al. Allergen challenge of peripheral blood mononuclear cells from patients with seasonal allergic rhinitis increases IL‐17RB, which regulates basophil apoptosis and degranulation
Song et al. Proteomic profiling of serum from patients with tuberculosis
US20070231842A1 (en) Detection of autoantibodies to cytokeratin 18 protein in patients with bronchial asthma and chronic rhinitis
WO2019195823A1 (en) Prediction and treatment of immunotherapeutic toxicity
CN115315523A (en) Triage method using nucleosome-free level
Ax et al. T2 and T17 cytokines alter the cargo and function of airway epithelium-derived extracellular vesicles
JP2024091650A (en) Pro-adm for prognosis of trauma-related complications in polytrauma patients
JP2023111913A (en) Antibiotic therapy guidance based on pro-adm
CN111094981B (en) PCT and PRO-ADM as markers for monitoring antibiotic treatment
Mishra et al. Role of P-gp and HDAC2 and their Reciprocal Relationship in Uncontrolled Asthma
US20150377907A1 (en) Diagnosis Of Rheumatoid Arthritis
CA3237899A1 (en) Markers and cellular antecedents of rheumatoid arthritis flares
CN111656189A (en) Antibiotic therapy guidance based on procalcitonin in patients with complications
KR100756972B1 (en) Composition for prevention treatment and diagnosis of chronic obstructive pulmonary disease
US20230146841A1 (en) Tnfaip3 as a biomarker for autoimmune diseases
Trinh et al. Transforming growth factor-β1 and eosinophil-derived neurotoxins contribute to the development of work-related respiratory symptoms in bakery workers
Wilantri et al. SAT0068 CIRCADIAN RHYTHMS OF IMMUNE SYSTEM IN HEALTHY INDIVIDUALS AND PATIENTS WITH RHEUMATOID ARTHRITIS
Al Mashhadani From Lübeck Institute for Experimental Dermatology (LIED) Supervised by Prof. Hauke Busch
Haw et al. TLR7 promotes smoke-induced lung damage through the activity of mast cell tryptase
van Wesemael et al. POS0395 ANTI-ACETYLATED PROTEIN ANTIBODIES IN RHEUMATOID ARTHRITIS (RA): CLUES FOR THE STARTING POINT OF AUTOANTIBODY RESPONSES IN RA
Roshanisefat Coronavirus and Multiple Sclerosis, Autopsy and Biopsy and Choice of Therapy
Yan et al. Online Repository Epithelium-derived Cystatin-SN enhances eosinophil activation and infiltration via interleukin-5 in chronic rhinosinusitis with nasal polyps
Lombardi et al. Detection of Xenotropic Murine Leukemia Virus Related Virus (XMRV) in Gulf War Illness: Role in Pathogenesis or Biomarker?

Legal Events

Date Code Title Description
AS Assignment

Owner name: STERNA BIOLOGICALS GMBH & CO. KG, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TUROWSKA, AGNIESZKA;BILLE, JOACHIM;REEL/FRAME:043854/0853

Effective date: 20170725

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
AS Assignment

Owner name: STERNA BIOLOGICALS GMBH, GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:STERNA BIOLOGICALS GMBH & CO. KG;REEL/FRAME:063881/0972

Effective date: 20220211

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 4